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Commentaries
On Being Grandfathered
Although I feel guilty, I thank my
lucky stars for being old enough not
to have to be recertified as a neurologist. Since I had been grandfathered
in, I didn’t pay much attention to the
implementation of this process, so I
don’t know how long ago this became
a requirement to remain a bona fide,
board-certified neurologist. I think it’s
a great idea too, which is why I feel
guilty that I haven’t voluntarily undergone recertification. On the one hand
I figure that this is one benefit of being old, but I practice “geriatric neurology.” I even participate in fellowship
training programs in geriatric internal
medicine, geriatric psychiatry and geriatric neurology. Who should know
better than I how limited our insight
becomes when we start to hear, those
of us not too deaf, the tiny splashes
those cortical neurons make when they
drop off the surface of our brains and
fall into the deep and spacious caverns
we call sulci? That’s probably why old
neurologists don’t like quiet places too
much.
My guilt is many layered. I believe in quality control. Real quality
control. Not the sort of quality control that JCAH requires, the “paper
trail” variety where what counts is not
so much the quality as the ability to
fill out a form that measures something
that presumably is related to quality.
A signed document that confirms a
meeting to discuss quality control is far
better than having quality. Like everyone else in the medical community I
care more if my surgeon is good than
if he got his two hours of risk management CME credits. One fairly reasonable measure of his knowledge,
although not his skill or judgment, is
his board status, and I think most patients would feel reassured to know that
she passed her recertification exam.
However, I think, why should I take it
and not my other elderly colleagues?
More important to me is my recollec-

70
Medicine and Health / Rhode Island

tion of the Neurology Board exams
themselves. The number of questions
that had nothing to do with clinical
neurology was impressive. I later discussed this with a neurologist who
helped create the test. He explained
that the test was meant to discriminate
passing and failing populations, and
this was most easily done by asking
highly technical questions that were
not relevant to clinical neurology.
I have been told that recertification exams are mainly clinical and are
relevant to the practice of neurology.
Unlike the board exams, one does not
have to know upon which chromosome each of the important mutations
is located. I believe that I am a competent neurologist, for all of adult neurology, and not just for my area of
focused interest. Yet I have chosen to
not sign up for the exam. I am unaware of any neurologist who has voluntarily signed up either. Would it
help in attracting patients? Would it
be seen as a plus to publicize one’s recertification? I doubt it. Once one
has been in practice for a period of
time, one has a reputation. A reputation is easily lost, but would passing
an exam burnish it? After all, neurologists frequently do EMGs and read
EEGs, yet few who do are certified in
electrophysiology. And they are reimbursed the same. Yet the difference in
quality does, in fact, make a difference.
Many neurologists will not accept the
EMG or EEG results from an unknown neurologist simply because the
quality spectrum is so wide.
I guess that one reason I use to
justify my not taking the exam, aside
from not wanting to invest a large effort, is that I have a reputation, I work
hard to keep up, and failing the exam
could only hurt me while passing it
would merely be expected.
When I think of my own recalcitrance in not mustering the courage to
recertify myself, I contrast this with a

prominent physician I was told about
who taught at a prestigious medical
school. He was the child of a parent
with Huntington’s disease, and therefore at 50% risk. Huntington’s causes
a triad of symptoms, one of which is
an alteration in behavior and another
is dementia. The doctor decided that
the only objective way to prove to himself that he had continuing competency, since he didn’t trust his
colleagues to make an honest assessment, was to take the board exam in
internal medicine every year. If he
failed he would stop practicing.
I am in awe of this. I could not
do it. I passed my boards, back when
I had a lot more brain cells than I do
now, with little room to spare. I did
not, and still do not equate a high score
on such an exam with any better clinical skills as a neurologist.
Now I have another concern to
contend with. There is a distinct possibility that in the next decade my
branch of neurology, Movement Disorders, may become a “recognized”
subspecialty, along with geriatric neurology, neuromuscular neurology, dementia, stroke, etc. in which case I may
“need” to pass a certification exam, although I can hope that the authorities
will feel some leniency to us “grandfathers.”
I believe that people like me
should not be grandfathered in, but
until I’m forced, I doubt that I will be
voluntarily signing up to take any exams.

– JOSEPH H. FRIEDMAN, MD

Murder, Most Foul, In a Medical School
Laboratory
Most people are content if they manage to excel in one
field. Oliver Wendell Holmes [1809-1894], however, could
confidently claim preeminence in the varied fields of poetry,
philosophy, epidemiology and higher education. Indeed, his
enduring fame as a writer [and father of an eminent juror] has
obscured the fact that his daily occupation had been medicine.
Holmes underwent his medical education at Harvard
and, in 1832, traveled to Europe for two further years of
clinical training before returning to Boston to open his office
for the general practice of medicine, on Tremont Row.
In 1842, Holmes began an epidemiological study of the
events surrounding a dreadful disease called childbed fever,
the principal cause, then, of maternal mortality. He concluded
that childbed fever was a form of generalized sepsis, that it
was contagious and that the vector of contagion was generally
the contaminated hands of the obstetrical physician or midwife. [Three years later, Semmelweis, in Austria, reached the
same conclusion.]
Holmes was highly regarded by his medical peers; and
accordingly he was appointed as the George Parkman Professor of Anatomy at the Harvard Medical School, and, in 1847,
he was selected as dean of the medical school.
His years at Harvard witnessed some wondrous events,
such as the inaugural use of a general anesthetic at Massachusetts General Hospital in 1846; but there also were events that
were less commendable, such as the brutal murder of Dr.
George Parkman, a Harvard medical graduate, Class of 1815,
and the benefactor of Holmes’ endowed professorship.
Newspapers called this murder, and the subsequent trial,
“the murder of the century.” It attracted journalists from as
far away as central Europe and threatened the stability, even
the integrity, of Harvard, particularly so, since the man accused of the murder was Harvard’s eminent Dr. John White
Webster, Professor of Chemistry.
The victim, George Parkman [1790-1849], was the scion
of a distinguished Boston Brahmin family and a philanthropist of note. His family’s real estate holdings allowed Parkman
to donate the land upon which the Harvard Medical School
was constructed [appropriately, on Parkman Street abutting
the Charles River, next to the Massachusetts General Hospital]. He also underwrote the endowment which supported
Holmes’ professorship.
Upon graduation from medical school, Parkman sailed
to Europe; but instead of studying in England, he elected to
go to France, specifically to study their radically new methods
for the compassionate care of the insane. He returned to Massachusetts, vowing to devote his medical career to the establishment of a hospital, a “retreat,” where the mentally afflicted
might be treated more humanely.
Parkman turned his great energies, and funds, to the design and construction of a modern mental hospital, an institution which was eventually the McClean Hospital, one of
this nation’s outstanding psychiatric centers. Parkman’s wish
to become its first director, however, was denied since the
hospital’s trustees feared that such an appointment would represent a conflict of interests.

In bitterness Parkman turned away from medicine and
concentrated his energies on the management of his father’s
vast realty holdings. People described him now as a tall, forbidding and autocratic man who was punctual at all times,
fastidious in habit and increasingly parsimonious. Much of his
income was derived from interest upon loans. And one of his
many customers was Professor Webster. In stark contrast to
Parkman, Webster was widely known as a gregarious soul,
musically talented, witty, an imprudent spender and incapable
of balancing his budget. Webster owed Parkman $2,400, and,
as of November 23, 1849, could not repay his debt.
The last time that Parkman had been seen alive on that
fateful day was during his walk to the medical school, where he
sought out Webster in his laboratory. Some witnesses recalled
hearing an exchange of harsh words. By nightfall the Parkman
family, deeply distressed that he had not returned, undertook a
wide but unsuccessful search.
A week went by with no sign of Parkman. An anatomy
assistant at the medical school, Ephraim Littlefield, dug
through one of the medical school walls to an area beneath
Webster’s laboratory. No reason had ever been given for this
exploratory excavation; but, whatever prompted Littlefield, he
nonetheless uncovered a freshly dissected torso and a few limbs.
Circumstantial evidence was sufficient for the state to indict
Webster for the un-witnessed murder of his colleague, Dr.
Parkman. The trial began 116 days later and it rapidly became
the preeminent news story in New England.
Harvard Medical School, now under the academic leadership of Oliver Wendell Holmes, was immensely distressed by
the trial. Holmes was asked to testify whether the recovered torso
might be Parkman’s. He declared that it was consistent with
Parkman’s general physique. Parkman’s widow, however, asserted
that it definitely was her husband’s body, based on her recognition of certain markings in the genital region. Furthermore, Dr.
Nathan Keep, Parkman’s dentist, identified a set of false teeth,
recovered from the furnace near Webster’s laboratory, as identical to the teeth he had made for Parkman. Thus, by the primitive forensic standards of the mid-19th Century and the damning
evidence that the two men had argued, the jury found Webster
guilty and he was hanged on August 20, 1850.
Harvard’s president, Edward Everett, declared that the
murder was “the most painful event in our domestic history.”
Only slowly did the academic luster of Harvard resume. Yet,
even two decades later, when Charles Dickens visited Boston,
his first request was to visit the room where Dr. Parkman was
alleged to have been murdered.
Holmes barely survived the rancor and dismaying publicity of this celebrated murder trial. He later resigned his deanship
and devoted the next few decades to an extended speaking tour
away from Boston. The name Parkman persists as a street in
Boston, as a professorship at Harvard, and even as a species of
house wren. John Audubon, the great naturalist and close friend
of Parkman, had named a species of wren [Troglodytes parkmanii]
in his honor “as an indication of the esteem in which I hold him,
and of the gratitude which I ever cherish towards him.”

– STANLEY M. ARONSON, MD, MPH
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Cancer Screening For Prevention and
Early Detection of Cancer
Arvin S. Glicksman, MD, and John Fulton, PhD
When we ask a presumably well individual to submit
to a procedure for the detection or prevention of cancer, it
is assumed that the risk-benefit overwhelmingly is favorable to the individual and that interventions, based upon
this information, can save lives. By this standard, the
Papanicolou Test is universally accepted as having a very
high benefit and very low risk. Over the last 50 years it has
saved millions of lives. Before the introduction of the “Pap
smear,” cervical cancer was the leading cause of cancer deaths
in women and these deaths usually occurred before the age
of 50. The regular Pap examination of women who are
sexually active made it possible to detect early cancer in a
curable stage. Pre-invasive cancer can be removed leaving
the reproductive integrity of the woman intact. Currently
under investigation are vaccines targeting strains of the
Human Papilloma Virus (HPV) responsible for the development of cervical cancer. The prospect of immunizing the
population against HPV is an exciting new opportunity
for the 21st century, but paradoxically, one which may not
reduce the complexity or cost of cervical cancer prevention
and screening. For example, there are many strains of HPV
in the world, some of which would be “covered” by the
vaccine, and others not, and infinite possibilities for HPV
mutation. These facts, combined with other givens, such
as less than perfect vaccine coverage in any given population, infection prior to vaccination, immigration of people
from geographic areas of low vaccine coverage, and the lessthan-perfect immunity afforded by any vaccine in any population, will assure the use of the Pap test (or its medical
descendent) for decades to come. Nonetheless, using HPV
vaccine and the Pap test promises to reduce disease burden
substantially in developed and developing societies, alike.
While there have been occasional outbursts of statistical reviews questioning the value of mammography, there
has been overwhelming support in the medical community for the value of mammography. In Rhode Island, where
we have one of the highest mammography utilization rates
in the country, we have seen significant down-staging of
disease at presentation with a concomitant improved survival rate for women with breast cancer. In Dr. Schepps’
paper, she addresses the issue of yet improving the value of
mammography by newer diagnostic modalities. While false
positive reports of mammographic abnormalities cause anxiety and apprehension for women (thus creating their own
impetus for test refinement), false negative reports are even
more concerning, given at present the still-narrow temporal window of opportunity for effecting long-lasting cancer freedom in breast cancer victims. By improving our
ability to locate and biopsy lesions in dense breasts and
other difficult situations, we can look forward to an im-
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provement in both the sensitivity and specificity of mammography, thus both the survival benefit and efficiency of
the test for all women.
Colorectal cancer in both men and women is the second leading cause of cancer death in Rhode Island. Identifying and removing precancerous polyps has been associated
with a decrease in the number of colon resections for
colorectal cancer. As Dr. Lidofsky points out, complete examination of the colon involves careful preparation, a timeconsuming, inconvenient, and uncomfortable process
considered odious by many. The procedure itself is invasive
and some patients resist having the “gold standard” procedure, colonoscopy. Newer, somewhat less invasive procedures may overcome some of the public resistance to
colorectal cancer screening while having the advantage, potentially, of fewer side effects such as perforation of the colon and peritonitis. Virtual colonoscopy, an x-ray procedure,
is not widely performed and may need fine adjustments
before it is “ready for prime time.” As proteomic research
proceeds, the identification of stool DNA associated with
malignant lesions has not been perfected, but some forms
of the new stool tests are now undergoing clinical trials to
establish specificity, sensitivity, and patient acceptability.
Notwithstanding these exciting improvements in colorectal
cancer screening, the 500 pound gorilla in the room is not
patient resistance to “things fecal,” but rather the high outof-pocket cost of colorectal cancer screening in our state. It
is one thing to ask a patient to follow the distasteful and
embarrassing steps associated with FOBTs and endoscopy
preps. It is quite another to ask that same patient to plunk
down $400 or more at the time of a colonoscopy as a pseudoco-pay. “Pseudo-” co-pay? Yes, indeed. The accepted use of
the co-pay in health care economics is to deter over-use of
less-than-lifesaving services, not to deter potentially life-saving screening tests prescribed according to nationally recognized guidelines (thoughtfully developed on the basis of
successful clinical trials). We think it is time to examine this
practice thoroughly in open debate.
Perhaps the biggest dilemma in cancer screening is what
to do with the information from a simple blood test, the
PSA, for detection of prostate cancer. Doctors Cohen, Schiff,
and Kelty discuss different PSA tests available and address
the issue of what is “insignificant prostate cancer.” On the
one hand, high grade prostate cancer has been diagnosed in
some young men with “normal” PSA values, and on the
other hand, we continue to find a considerable a number of
low grade and medium grade prostate cancers in older men
who will most likely die with, not of prostate cancer. The
dilemma with an abnormal PSA finding is whom do we
biopsy and whom should we treat? For some populations

at high risk, such as African-American men, we believe that
screening is necessary starting at age 40, despite the risk of
side effects (incontinence, impotence) inherent in current
treatments for prostate cancer. Other populations, at various degrees of lower risk, require different screening regimens to balance the potential benefits and costs of
treatment. One thing is certain, however. As we debate what
to do with PSA findings, the test is being widely used, resulting in a stage migration to more local disease. Less men
are presenting with advanced disease de nouveau, and the
death rate from prostate cancer is declining among highrisk and low-risk men, alike. Although we have a long way
to go before we are comfortable in the way we utilize PSA
test results, we know we are on the right road.
One of the least invasive and least frequently performed
screenings is total skin examination. As Dr. Cordova and
Dr. Weinstock point out, skin cancer is the most common
cancer. It is “on the surface” and easily detected, if someone skilled in the identification of skin lesions looks for it.
In Rhode Island, where many people enjoy outdoor activities associated with high-risk skin exposure, skin cancer and
particularly melanoma is a high risk problem. Most primary care providers understand the importance of examining the skin, but how many do total skin examinations of
high-risk (e.g., fair-skinned) individuals during annual
physicals, or alternatively, assure that high-risk patients get
evaluated regularly by a dermatologist? How many primary
care providers are skilled at identifying squamous cell carcinoma of the skin, a deadly disease? Even malignant melanomas may be difficult to identify without special skills
and considerable experience. Most skin cancers can be prevented by decreasing exposure to the sun, and since this is
cumulative damage, prevention should start at a very early
age. Both prevention and detection of skin cancer has not
been in the forefront of the public’s attention, and yet preventing skin cancer is one of the easiest interventions to
effect. Awareness of the dangers of sun exposures (and tanning booths), particularly in the “Ocean State,” needs to
start in grade school and emphasized by teachers, parents,
coaches, and everyone else involved with the youngsters
who are sent out into the noonday sun to play. The US
Preventive Services Task Force has not found “sufficient
evidence” to recommend regular total skin evaluation for
the average adult. Could this be because data on skin cancer, except for melanoma, are not recorded in tumor registries across the country? Or that many dermatologists do
not believe squamous carcinoma of the skin is a problem
(Dr. Weinstock is not one of them)? Awareness as adults of
“cumulative sun damage” and the regular performance of
total skin examination should not be a haphazard event,
but should be practiced regularly, joining other effective
cancer screening tests.

Arvin S. Glicksman, MD, is Director, Rhode Island Cancer Council, Inc.
John P. Fulton, PhD, is Associate Director, Disease Prevention and Control, Rhode Island Department of Health, and
Clinical Associate Professor of Community Health, Brown
Medical School.

CORRESPONDENCE:
Arvin S. Glicksman, MD
Rhode Island Cancer Council, Inc.
249 Roosevelt Avenue, Suite 201
Pawtucket, RI 02860
Phone: (401) 728-4800
Fax: (401) 728-4816
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HPV Vaccines – Why Aren’t They the
Answer Yet?
Amy Kirkpatrick Brown, MD, MPH, and Richard G. Moore, MD
Cervical cancer remains an important public health problem worldwide,
particularly in areas without effective
screening programs. Even in the United
States, with screening widely available,
more than 12,000 new cases of cervical cancer are diagnosed annually and
approximately 4,200 women die from
what is an essentially preventable disease.1 The worldwide burden of disease
is significantly higher, with up to
500,000 deaths per year. Cervical cancer is the leading cause of female cancer death in many areas. Although
screening programs can be effective
when well-implemented, limited resources have hindered their development in many parts of the world. In
addition, a significant segment of the
population remains unscreened even
where programs are available. In the
United States in 1994, approximately
20% of women between 18-64 years
old had not undergone Pap smear
screening within the previous three
years.2
The recognition in the 1980s that
the human papillomavirus (HPV) is
the causative agent for 95% of cervical
cancers provided opportunities for prevention, treatment, and preventive and
therapeutic vaccinations. Such vaccinations, if effective, would have a profound impact on the incidence of
cervical cancer, especially in areas without effective screening programs. Several challenges remain to be overcome
however prior to widespread implementation of HPV vaccination programs.

HPV BACKGROUND
The human papillomavirus is a
non-lytic double stranded DNA virus.
There are over 100 identified HPV
types, almost half of which infect the
anogenital region3. Of these, a subset
of oncogenic types have been identified.3,4,5,6 A study by Munoz et al, identified 15 high risk and 3 probable high
risk types which are associated with an
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odds ratio of 158 for the development
of cervical cancer7.
The HPV viral genome consists of
9 open reading frames encoding 7 early
genes (E1-E7) and 2 late genes (L1 and
L2). E1-E7 are responsible for viral
propagation and L1 and L2 encode the
viral capsid proteins. L1 is more abundant than L2, accounting for approximately 80% of the capsid8. The L1 and
L2 capsid proteins are necessary for
initial infection of the basal layer of
epithelium, however, once the virion
has been internalized, these proteins are
no longer accessible to the host immune system. Once inside the cell, the
E1 and E2 proteins initiate and maintain viral replication. It is the E6 and
E7 proteins that provide the HPV virus with its oncogenic potential. E6
binds the tumor suppressor p53 and
stimulates its ubiquitination and subsequent degradation, resulting in decreased apoptosis. E7 binds to the
tumor suppressor pRb, leading to its
inactivation and therefore uncontrolled
cellular proliferation.
Since the majority of HPV infections do not result in malignant transformation, an additional step is
necessary. In benign HPV lesions, the
viral genome remains separate from
that of the host, existing in episomal
form. This allows normal transcription
and translation of the E2 gene, whose
product suppresses E6 and E7. In lesions with malignant potential, the
HPV DNA integrates into the host
genome. This integration occurs within
the E2 open reading frame, resulting
in a loss of the E2 protein. This loss of
E2 eliminates the suppression of E6

and E7 thus allowing them to exert
their effects on their target tumor suppressor genes, p53 and pRb respectively.

HPV EPIDEMIOLOGY
NATURAL HISTORY

AND

HPV is the most common STD
in the United States3 with estimates
that half of all sexually active adults
have had an HPV infection9; the Institute of Medicine has estimated the annual cost of HPV related disease at
$10billion.10 Over 95% of invasive cervical cancers have detectable HPV
DNA.11 HPV 16 is the high risk type
accounting for the largest proportion
of invasive cancers, approximately half,
with some geographical variation.
Other common high risk types are 18,
31, and 45 and together with HPV 16,
these four subtypes are detected in 80%
of cervical cancer lesions.
Following infection with HPV,
there is a significant lag prior to the
development of cervical cancer. The
success of screening programs has been
due to the fact that HPV induces a series of recognizable pre-malignant lesions prior to the development of
invasive carcinoma that can be successfully identified and treated. A substantial percentage of these lesions will
regress spontaneously however, even
without treatment, suggesting continued host immune response even after
initial infection.
During this time, the natural host
defenses may successfully clear the infection. Both humoral and cell-mediated responses have been shown to be
important in the natural response to

HPV infection.12 In one study by Ho,
72% of women with HPV16 DNA in
cervical secretions developed antiHPV16 antibodies. The mean time to
seroconversion following detection of
cervical HPV DNA was 8 months, and
57% of women had seroconverted
within one year13. Another study by
Viscidi showed that 40% of women
with detectable cervical HPV 16 DNA
were seropositive as compared to 15%
of those without detectable DNA14.
Over 5 years of follow-up, 67% of
women initially HPV16 DNA positive
cleared their infection, and 92% of
women positive for any HPV cleared
their infection. During the same time
period, 14% of women acquired a new
HPV infection.15
The natural immune response to
HPV infection has also been demonstrated by the association of naturally
regressing lesions with large T-cell infiltrates. Low levels of HPV specific
killer T cells against E6 and E7 have
been detected in both CIN3 and invasive cancer.16 The increase in lesion
progression in immunosupressed patients further implicates host defenses
in the clearance of HPV infection.

GENERAL PRINCIPLES
VACCINATION

OF

Broadly stated, the goal of any
vaccine is to induce long-lasting immunity without causing infection. This
immunity can be from the induction
of cell mediated or humoral responses,
or both. The majority of population
based vaccines in use today are prophylactic, with the goal of preventing infection. To be effective, these vaccines
must thus be given prior to exposure
to the pathogen. Therapeutic vaccines
on the other hand stimulate the host
immune response to an already established infection. For HPV, both prophylactic and therapeutic vaccines have
been developed and will be discussed
in detail later.
Animal models are important in
the early stages of vaccine development,
and several animal papillomaviruses
exist and have been used to elicit understanding of both the natural immune response to HPV infection and
the effect of a variety of vaccines. The

most commonly used naturally occurring animal models are the cotton-tail
rabbit papillomavirus (CRPV), the
bovine papillomavirus (BPV), the
rhesus monkey papillomavirus
(RhPV) and the canine oral
papillomavirus (COPV). The CRPV
is probably the best characterized system, and prevention of infection following vaccination with capsid
proteins as well as regression of lesions
following vaccination with early proteins has been shown.17,18 Vaccination
has also been shown to successfully
prevent development of papillomas
caused by COPV and BPV.19,20
To
study
the
human
papillomaviruses in animal models,
xenografts of HPV infected cells can
be transferred to nude mice. Studies in
such mice have been promising. Both
parenteral and nasal immunizations
have shown good antibody responses,
with increased antibody titers in mucosal secretions following intranasal
immunization21,22. Oral vaccine administration has demonstrated IgG and
IgA responses, though at lower levels
than achieved with parenteral administration23. Mucosal administration
elicits both systemic and mucosal immune responses24.

PROPHYLACTIC HPV
VACCINES
Prophylactic vaccines against
HPV would have the benefit of being
able to prevent HPV infection and thus
decrease not only cervical cancer incidence but also decrease the incidence
of dysplastic precursor lesions. To be
effective, a prophylactic vaccine must
induce a response to viral antigens
present on the intact virion. The capsid
proteins L1 and L2 would be the natural targets of such a vaccine. Both systemic antibodies and local mucosal
antibodies in the genital tract would
be needed for such a vaccine to be effective. Despite much recent development, challenges to a prophylactic
vaccine remain. HPV L1 IgG’s are not
reactive across types, and a vaccine
would thus provide protection only to
the type or types included in the vaccine. Given the multiple oncogenic
HPV types, a vaccine that would sig-

nificantly decrease the incidence of cervical cancer would have to target at
least the most common types. The
magnitude of regional differences in
type distribution is still not entirely
clear, and vaccines may need to be tailored to the region in which they are
to be used14. The length of immunity
provided by a prophylactic vaccine is
also of concern. The potential exposure time to HPV is very long, essentially beginning at the onset of sexual
activity. The immunity provided from
a prophylactic vaccine would need to
be equally long, or else booster doses
would be required.
The target population for a prophylactic HPV vaccine could also pose
unique difficulties compared to many
existing vaccines. To ensure immunity
prior to exposure, it would be necessary to vaccinate adolescents, requiring parental acceptance. Such parental
acceptance of vaccination for a sexually transmitted disease cannot be assumed and has not been proven.
Adolescents also do not present for
medical care as often as younger pediatric patients. If life-long immunity
could be provided, HPV vaccination
could be added to the schedule of
childhood immunizations, much as the
Hepatitis B vaccine has recently been
introduced. Realistic estimates of the
fraction of the target population that
would actually receive the vaccine must
be determined before the impact of any
vaccine can be predicted. An additional
concern regarding the appropriate target population is the role of the vaccination of males. Although females are
the subset directly affected by HPV
related cervical cancer, if the prevalence
of infection in males can be decreased
by vaccination, the exposure to females
will be further reduced. Males would
also benefit directly if the low risk subtypes which are responsible for genital
warts were included in a prophlyactic
vaccine. It is likely this strategy would
increase the appeal of vaccination to
the male population. It must be also
be remembered that due to the natural
history of HPV infection and cervical
carcinogenesis the impact of prophylactic vaccination of adolescents will
not be seen for many years. As well,
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the global availability and use in under-developed countries would have to
be addressed.

THERAPEUTIC HPV VACCINES

Therapeutic vaccines are designed
to be given to patients already infected
with HPV. This would require different antigenic targets than prophylactic vaccines, as once the virus has
become intracellular the capsid proteins are no longer expressed. The E1
and E2 proteins which are expressed
in cells with active viral replication
would be appropriate targets for vaccines aimed at patients with early
CIN25. The E6 and E7 proteins on the
other hand would need to be targeted
in vaccines directed against high grade
or invasive disease where the viral genome has integrated into the host
DNA and E2 is no longer expressed.
One major limitation of therapeutic
vaccines in patients with invasive disease is that cervical cancer is associated
with some degree of immunosuppression and downregulation of HLA
Class I antigen presentation. HPV
derived CTL epitopes for HPV16 E6
were unable to recognize cancer cells
containing HPV16 E6 due to decreased HLA expression and decreased
TAP transport proteins.26 Results in
animal and clinical trials of therapeutic vaccines have been somewhat disappointing as well.27,28

TYPES

OF

VACCINES

Several different strategies for vaccine production have been explored as
options for HPV vaccines. Live attenuated or heat inactivated vaccines are
not feasible for HPV vaccination due
to the extreme difficulties in propagat-
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ing HPV in culture.29 Studies of the
response of both animal and human
subjects to HPV vaccinations of any
type have been greatly facilitated by the
demonstration that serum antibody titers do in fact correlate with neutralization ability.30

RECOMBINANT LIVE VECTOR VACCINES
Recombinant live vector vaccines
are non-pathogenic or attenuated bacteria or viruses engineered to express
the antigen or antigens of interest.
These vaccines induce both antibody
and cell-mediated immunity, often
with just one dose. Multiple antigens
can be expressed in a given vector vaccine, providing the potential to target
multiple HPV types with a single vaccine, as well as combined prophylactic
and therapeutic vaccines. Unfortunately, vector vaccines cannot be given
to immunocompromised patients. This
could be a significant obstacle in many
areas of the developing world where the
prevalence of HIV is high, and the serostatus of vaccine candidates may not
be known.
A given vector can be used only
once for vaccination of an individual,
as prior immunization induces tolerance to the vector and prevents the
desired immune response. This limitation would require the development
of HPV vaccines using vectors not currently used for vaccination, or the incorporation of HPV antigens into
existing vector vaccines.
Several companies and academic
institutions are currently developing
vector vaccines. The TA-HPV vaccine,
targeting HPV16 and 18 E6 and E7
in a vaccinia vector has been shown to
stimulate a good antibody response,
but clinical outcomes have not yet been
evaluated.31 A combined therapeutic/
prophylactic vaccinia vector vaccine is
under development in China targeting
HPV16 L1 and E7. Wistar has developed both adeno and vaccinia vector
vaccines for HPV16 L1 and HPV16
and 18 E6 and E7 that can be administered intranasally. Both have been
shown to simulate serum and vaginal
antibody responses.31 A Venezuelan
equine encephalitis vector vaccine is in

preclinical trials by Wyeth, and a novel
vaccinia vaccine for HPV16 E6 and E7
with lysosomal targeting is in Phase I
trials at Johns Hopkins.31

PEPTIDE OR PROTEIN
VACCINES
The main advantages to peptide
and protein vaccines are their safety
and low cost. The T-cell response is lessened, however, and an adjuvant is often
required
to
stimulate
inflammation. Multiple vaccine doses
are required. Peptide vaccines are also
limited by HLA specificity of the target epitopes.32
Animal studies have demonstrated
good clinical responses to HPV protein vaccines.17 The TA-GW vaccine
(an HPV6 L2/E7 fusion) from Cantab
has shown clearance of genital warts
and decreased recurrences in Phase I
and II trials in humans.31 The TA-CIN
vaccine for cervical cancer prevention
is in Phase I trials31 following successful trials in mice33. Other peptide and
protein vaccines are being developed
and tested, mostly targeted to therapeutic uses.

NAKED DNA VACCINES
Bacterial plasmids can be engineered to incorporate HPV genes
which can then used for vaccination.
Both antibody and cell mediated responses are stimulated, and protection
is long-lasting since the antigen continues to be produced. DNA vaccines
are relatively cheap, and their long shelf
life and stability would make them
particularly attractive in developing
countries where it can be difficult to
maintain a cold chain. Potential risks
from DNA vaccines include incorporation of the bacterial plasmid into the
host DNA, although this risk remains
theoretical.

VIRUS-LIKE PARTICLES
(VLPS)
Virus-like particles are formed
spontaneously by the HPV capsid proteins L1 and/or L2. The discovery of
this phenomenon has greatly accelerated the pace of vaccine research given
the difficulties in growing intact HPV
viruses in culture, and VLPs are cur-

rently the most advanced line of vaccine development. Both antibody and
cell-mediated response are stimulated
by VLPs, and vaccines with combinations of VLPs from more than one
HPV type have also been developed.
Lenz demonstrated the activation of
dendritic cells by papilloma virus VLPs,
resulting in a dominant T-cell response.34 Individually, responses to L1
VLPs are type specific, although some
cross-reactivity has been seen in both
animal and human studies if L2 is included.35,36,37 The VLPs alone are useful only as prophylactic vaccines, since
the capsid proteins are no longer expressed once the virus has moved into
the epithelial cell.
Chimeric VLPs (cVLPs) have
been developed to overcome this limitation by incorporating other viral antigens inside the capsid VLP. These
cVLPs provide the potential for combined therapeutic and prophylactic
vaccines. cVLPs have been shown to
stimulate a dendritic cell response to
both the capsid proteins and an added
E7 peptide.38 Animal studies have demonstrated both regression of pre-existing tumors and protection against
tumor challenge following vaccination
with cVLPs.39 One potential clinical
obstacle to effective vaccination with
VLPs is that although dendritic cells
are activated by VLP vaccines, Langerhans cells are not, despite their internalization of VLPs.40,41 This could
theoretically limit the mucosal response
to VLP vaccines.
A variety of VLPs have been studied in humans. They have consistently
been safe with minimal side effects, and
good antibody responses have been
detected with both parenteral and intranasal administration.42-48 A recent

trial showed that 3 doses of an HPV16
VLP vaccine provided 91% protection
against any HPV16 infection and
100% protection against persistent infection. The incidence of persistent
HPV infection was 3.8% in controls
versus 0% in immunized subjects.49
Phase III trials with CIN endpoints,
as well as with multivalent vaccines, are
currently underway.

If vaccination is
introduced in a
way that does
not allow for at
least a
reduction in
screening, the
costs may be
prohibitive in
many areas.
The length of immunity from
VLP vaccines has not yet been determined however. In animal studies of
the CRPV, titers decreased from
1:10,000 2 weeks following vaccination to 1:100 after 12 months, with
concomitant decrease in clinical protection.50 It is also not known what
level of serum antibodies is required for
adequate protection from infection.
Other challenges of VLP vaccines
are logistical and financial. Their production is expensive, and the requirement for a cold chain could
significantly limit their feasibility in
developing countries, where unfortunately the need is greatest.

PLANT BASED
VACCINES

AND

EDIBLE

Ease of administration and production are the obvious strengths of plant
based vaccines. Genetically engineered
plants can produce viral antigens, and
have been shown to be capable of generating HPV capsid protein VLPs.51,52
In mice, ingestion of a potato engineered to produce HPV antigens resulted in antibody production, although
at a significantly lower level that that
resulting from direct vaccination with
VLP’s.51 Current work involves mostly
the potato and the tomato.

EPIDEMIOLOGIC CONCERNS
The impact of any HPV vaccine
on a population level will depend on
several factors. First, the vaccine’s effectiveness and the length of immunity
induced. Second, the percent of the
population at risk who actually receives
the vaccine, or the vaccine coverage.
Finally, the percent of cervical cancer
caused by the HPV type or types included in the vaccine, known as the
population attributable fraction(PAF).
A meta-analysis has estimated the PAF
of HPV16 at 27-44% depending on
its prevalence in the population.53
A vaccine with 100% efficacy
against types 16 and 18 is predicted to
prevent 60% of high risk HPV infections, 46% of CIS, and 47% of invasive cancers54. Several researchers have
modeled the impact of HPV vaccination on cancer incidence with a variety of baseline assumptions.2,11,35,55-57
One estimate of the number of vaccinations required to prevent a single case
of cervical cancer, given 90% efficacy
and inclusion of the 4 most common
oncogenic types, ranged from 200-350
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vaccinations to prevent one cancer diagnosis55 The possibility of serotype
replacement still requires further investigation.58 Will other serotypes increase
in prevalence as those targeted by a
vaccine decrease? If so, the impact on
the overall incidence of cervical cancer
could be blunted.
The effectiveness of the vaccine
itself is not straightforward to measure,
and the appropriate endpoints for clinical trials are not clear.59 Lessons from
the use of surrogate endpoints in
chemoprevention trials must be considered60 and ultimately, clinical decisions must be made on clinical
endpoints. Both logistical and ethical
issues must be considered in selecting
trial endpoints. While the ultimate goal
of vaccination is a decrease in cervical
cancer, it is neither feasible nor ethical
to follow patients without intervention
until the development of cancer. High
grade lesions have been proposed as an
alternative endpoint that will both allow shorter duration studies and not
put subjects at undue risk. Trials with
this end point would still require several years of follow-up. Feasibility studies have attempted to estimate required
sample sizes and length of follow given
varying endpoints.61,62 With a 70% effective vaccine against HPV16, 1000
subjects would be needed for an endpoint of HPV16 infection, and 15,000
for an endpoint of CIN3.62 Acquisition
or persistence of HPV DNA in cervical samples is a potential endpoint that
would allow for shorter trials, although
the small percent of infection that proceeds to cancer, and the lack of definitive predictive cofactors, would make
it difficult to extrapolate from such a
study to the ultimate endpoint of invasive cancer.
The length of immunity will also
impact the ultimate effect of vaccination. The more doses that are required
or the need for a booster dose will decrease overall coverage. Animal studies
suggest that immunity from VLP vaccinations may be dependent on booster
doses.50 In the US and Europe the
prevalence of HPV infection decreases
with increasing age so some degree of
waning immunity may be acceptable.
Unfortunately this is not true world
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wide, and the populations most in need
of booster doses may end up being
those with the least infrastructure to
receive them.
Vaccination coverage will also depend on the choice of target population, the societal acceptability of
vaccination, and the infrastructure for
vaccine administration. A long lasting
vaccine that could be incorporated into
the current childhood vaccination
schedule would likely have the greatest coverage, unless societal acceptance
of STD vaccination for children limits
its use. A combined therapeutic/ prophylactic vaccine given to adults, while
more socially acceptable, would be
likely to miss a greater percentage of
the population.
Finally, vaccination infrastructure
will be particularly important in developing countries, where trained providers are limited and cost and cold-chain
requirements could be prohibitive. The
effect of vaccination on current screening programs must also be considered.
As it is unlikely that any vaccine will
be capable of preventing all high risk
HPV infections, some screening program must remain in place. This will
also be necessary to detect the small
proportion of cervical cancers that are
not HPV-related. The intensity of this
screening will to some degree depend
on the PAF of disease that the HPV
types NOT in the vaccine account for.
The effect of the vaccine on the prevalence of low grade lesions must be considered. If a vaccine is successful in
preventing high grade lesions and cancer, but does not also decrease the
prevalence of low grade lesions, current
triage guidelines will need to be revised
to spare patients with low grade lesions
unnecessary testing and intervention.
The effect of a vaccine on the ultimate
prevalence of cervical cancer will also
depend in part on the behavior of vaccinated women. The fewer HPV types
included in the vaccine, the more important continued screening will be. If
vaccinated women mistakenly believe
they are no longer at risk for cervical
cancer and drop out of screening programs, the ultimate impact on cancer
incidence will be decreased.
The financial implications of

HPV vaccination must also be considered. Since screening will not be able
to be eliminated, cost savings with vaccination will come primarily from decreased treatment costs of high grade
lesions and invasive cancer. If vaccine
boosters are necessary, the cost savings
will be reduced.

CURRENT CLINICAL TRIALS
Several trials are underway evaluating potential HPV vaccines. Although not a comprehensive list, every
effort was made to identify them.

CONCLUSIONS
Several obstacles to the wide
spread implementation of an HPV vaccine are both scientific and programmatic. Perhaps the most important
scientific obstacle is the lack of definitive data on the length of immunity
provided by any of the HPV vaccines
currently under development. Clinical
follow-up is not yet long enough to
accurately determine length of protection. While serum antibody levels may
be used as a surrogate marker of immunity, the levels required to provide
protection against HPV infection is not
clear, nor is the importance of cervical
IgA levels as compared to serum IgG
levels, and studies in both animals and
humans have shown decreasing serum
titers over time following vaccination.50
Before a vaccine is offered to the public, we are obliged to be able to provide an accurate estimate of the length
of protection such a vaccine will provide. The experience with the measles
vaccine in the 1990s cannot be forgotten, where unrecognized waning immunity resulted in an epidemic of cases
in adolescents and young adults.63 If
boosters are required, the population
coverage will likely be significantly reduced resulting ultimately in a diminished effect on cancer incidence.
The impact on screening programs also needs to be determined
prior to implementation of widespread
vaccination. If a vaccine against a single
subtype such as HPV16 is made commercially available, even if 100% vaccine coverage is achieved, screening
programs must continue to detect the

half of cervical cancers not caused by
this subtype. As well, the possible shift
in viral types with excluded types becoming more prominent and resulting
in an increasing number of cervical
cancers. Screening programs must also
continue for the millions of women
who have already been exposed to
HPV, even if a 100% effective prophylactic vaccine were to become available.
If vaccination is introduced in a way
that does not allow for at least a reduction in screening, the costs may be prohibitive in many areas. Combination

vaccines to multiple types would be
better able to impact both the ultimate
incidence of cervical cancer and the
need for screening programs, even
though the development of such multivalent vaccines is not as far advanced
at this time.
The societal acceptance of vaccination must also be established and
decisions must be made whether to
vaccinate males, and whether to include low risk people in a combination
vaccine. Although this would increase
the initial cost of vaccination programs,

it would ultimately decrease the female
exposure to the virus. It has been estimated that a prophylactic vaccine given
to females only would be 60-75% as
effective as if both males and females
were vaccinated.54 Education and information will need to be provided to
both women and men regarding the
benefits and limitations of vaccination.
In summary, although an effective
prophylactic HPV VLP vaccine is likely
to be technically feasible within the
next several years, several questions
critical to its success remain unanswered. The length of protection, the
population coverage likely to be
achieved, the feasibility of vaccinations
in resource poor areas, and the ability
to revise current screening programs,
will all impact the endpoint of cervical
cancer incidence. Given the numbers
of women required for large scale trials with clinical endpoints, collaboration between the disparate groups
working throughout the world on vaccine development is crucial. It would
be both medically and fiscally foolhardy to introduce widespread vaccination before these technical and
programmatic issues are addressed.
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Breast Imaging: The Role of Alternative
Diagnostic Modalities
Barbara Schepps, MD
Breast cancer continues to be the
highest incident cancer and the second
leading cause of cancer-related death in
US women. This year approximately
275,000 women will be diagnosed with
the disease and 40,110 will succumb.1
American women have a one in seven
risk of developing the disease and factors
such as personal history of breast or ovarian cancer, atypia, lobular carcinoma
insitu or genetic aberrations such as
BRCA1 or BRCA2 increase the risk for
developing breast cancer. While patients
with BRCA mutations comprise only
about 5 to 10% of women with breast
cancer, their risk for developing breast
cancer is 50 to 85% .2 The gold standard for breast cancer detection is mammography. Screening mammography, in
randomized controlled studies, has been
shown to decrease breast cancer mortality by 24%.3 For each 1000 women who
are screened, breast cancer is detected in
5 to 7 at first screen and two to three on
subsequent regular annual screenings.
However, mammography does not
identify all breast cancers. It had serious
limitations in discovering tumors in
women with dense mammary parenchyma and further lacks the ability to
characterize lesions at screening. While
many lesions can be characterized with a
diagnostic mammogram, some abnormalities rely on the use of other imaging
modalities and imaging-guided interventions. It is the goal of this paper to discuss the role of these alternatives.
A common misconception is that
digital mammography is a different examination from film screen mammography. The digital mammogram merely
employs a different image receptor; the
image is acquired electronically rather
than with film-screen. Although the
image obtained can be viewed as film,
in most practices it rarely is, but is
viewed on a high-resolution computer
monitor. These images can be stored
electronically, eliminating the need for
film, and images can be sent electronically for remote viewing. For the pa-

80
Medicine and Health / Rhode Island

tient, the procedure is faster because the
images are evaluated in real time and
there is no wait for film processing.
Most patients perceive the examination
to be more comfortable. The quality of
the images obtained is equal to filmscreen mammography. Digital mammography is superior in assessing the
dense breast because the image can be
windowed and leveled for improved tissue contrast. The radiation dose is
about the same, although slightly less
for the patient with dense breasts.
Breast ultrasound has advanced beyond the differentiation of solid versus
cystic masses with the advent of the
higher frequency transducers in the early
1990s. To perform breast ultrasound, a
transducer with a frequency in excess of
7.5 mHz is necessary. At this time, breast
ultrasound is neither a routine screening
tool nor does it replace mammography
as the first line of evaluation for palpable
masses except in the peripubertal patient,
the patient with dense breasts with a palpable mass or in patients with metastatic
disease and a negative mammogram.
There are ongoing studies both in Israel
and by ACRIN (American College of
Radiology Imaging Network) evaluating ultrasound as a screening tool. To
date, the variability of both equipment
and operators, and the labor intensity required are substantial deterrents for using ultrasound as screening.
Ultrasound now plays a routine role
in assessing palpable breast masses, characterizing mammographically detected
masses, evaluating focal breast pain, evaluating tumor size, assessing response to
neoadjuvant chemotherapy, staging the
axilla of cancer patients, and for guiding
interventions such as cyst aspirations or
biopsies. The ability of ultrasound to characterize masses was first noted in the early
1990s when Fornage began evaluating fibroadenomas and found that the length
to anteroposterior dimension of the fibroadenoma was greater than 1.4 in 86
percent and less than 1.4 in 100% of
malignant tumors. 4 This was followed

by a seminal article by Stavros in 1995
that evaluated 750 solid masses and extrapolated from these cases criteria to distinguish malignant from benign masses. 5
While there are limitations, theses studies
were the beginning of the widespread use
of ultrasound to characterize solid breast
masses.
Imaging-guided biopsies have transformed the diagnosis and management of
benign and malignant breast masses. With
the advent of the computerized stereotactic equipment, stereotactic breast biopsies
were first introduced in Sweden in 1976
and in the United States in the late 1980s.6
Stereotactic needle-guided biopsies have
been performed in Rhode Island since
1991. The stereotactic breast biopsy is a
mammographically (x-ray) guided procedure that pinpoints breast lesions to within
1-2 mm. The procedure may be performed with a special table where the patient lies prone or with conventional
mammographic equipment with the patient upright. Each has advantages. With
the prone table there is less patient motion
and less syncope, and the patient does not
view the biopsy being performed. However, the add-on device for the standard
mammographic unit is far less expensive
and suits the low volume situation more
ideally. Mammographic guidance (stereotactic biopsies) are reserved for those lesions
that cannot be seen with ultrasound.
Ultrasound guided biopsies require
the use of ultrasound equipment with high
frequency transducers. Any lesion that can
be seen with ultrasound should use ultrasound guidance to guide the biopsy to
ensure that the actual lesion itself is first
characterized. If the mass is a cyst, no further intervention is required unless the cyst
is painful or its sonographic appearance is
complex. Ultrasound guidance ensures
complete aspiration of cysts. If a cyst does
not aspirate completely, biopsy should
be performed. Ultrasound ensures accurate sampling of both palpable and nonpalpable solid masses. Even palpable
lesions are more accurately sampled with
ultrasound guidance.

A variety of needle systems are available to perform both stereotactic and ultrasound-guided biopsies. These range
from needles of tiny caliber (FNA) to
larger needles (9-14g) spring-loaded or
vacuum assistance for so-called large core
needle biopsies. The use of FNA is limited both because of the paucity of qualified cytopathologists and the inability to
determine whether an identified tumor
is invasive. The accuracy of image-guided
biopsies is reported in several series to be
greater than 98%.
The latest tool in the breast imaging
armamentarium is magnetic resonance
imaging (MRI). First used in 1986, its
value was impaired due to insufficient
standardization of the technique, lack of
reproducibility and the need for intravenous contrast injection. Further requirements include an MRI unit with field
strength of 1.5 Tesla or greater and a dedicated breast coils. To perform the procedure for the detection of breast cancer the
equipment must also be equipped to employ high spatial and temporal resolution
and create thin slices. Since the examination is restricted to the “closed” magnet,
patients with claustrophobia are excluded.
The exam takes about 25 minutes. Furthermore, breast MRI is highly sensitive
but not highly specific, with reports of sensitivity for invasive breast cancer approaching 100%. For DCIS, reports of sensitivity
range from 50 to 90%. For DCIS, MRI
and mammography are complementary
with mammography detecting five to
10% of the cases that are not detected with
MRI because of the presence of
microcalcifications.7
Both sensitivity and specificity depend on patient selection, MR technique,
level of experience, interpretation guidelines an intimate understanding of mammographic images for correlative
purposes. A variety of issues can affect
MRI interpretation. MRI characteristics
of benign and malignant lesions can overlap. Hormonal status of the patient can
affect the image and ideally, for the menstruating patient, the exam should be
performed on days six through 18 of the
menstrual cycle. Hormone replacement
therapy can affect the images as well.
Limitations of the study include a significant false positive rate, with one false
positive per 5 to 10 studies. Other limi-

tations include the need to be able to biopsy with MRI guidance since a certain
number of lesions are not detected by
other imaging modalities or by physical
examination. Clearly, the interpretation
is dependent upon the expertise of the
radiologist in reading breast MR, breast
ultrasound and mammography.

The latest tool
in the breast
imaging
armamentarium
is MRI.
There are now numerous indications for breast MRI. It is indicated preoperatively for staging newly diagnosed
breast cancer because the findings may
alter the extent or type of surgery
planned. It is also valuable in assessing
response to neo-adjuvant chemotherapy.
In patients with a history of breast cancer, it is useful in assessing post-operative residual tumor as well as for disease
recurrence. Other indications include
evaluating for occult tumor in patients
with metastatic disease in the axilla
whose mammogram, ultrasound and
physical examination are negative.
Breast MRI should also be used to
screening high risk women, particularly
those with genetic mutations such as
BRCA1 and BRCA2, in women who
have a first degree relative with premenopausal breast cancer, and in those
women who have a personal history of
breast or ovarian cancer particularly if
their mammogram demonstrates dense
breast tissue. In an article by Kriege et
al, MRI was shown to be more sensitive
than mammography in detecting tumor
in women with an inherited susceptibility to breast cancer.8 At the current
time breast MRI is not indicated for
routine screening, not only because of
expense, but also because there is a high
incidence of false positivity necessitating an increased number of biopsies.
Other contraindications include the
presence of pacemakers, aneurysm clips,
or claustrophobia. MRI does not replace mammography as a screening tool
for the general population.

In summary, mammography remains
the gold standard for breast cancer screening. While ultrasound and image-guided
interventions have become standard ancillary procedures in breast cancer diagnosis,
MRI now begins to play an increasingly
important, but limited, role in assessing for
breast cancer in selected groups.
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Detection and Prevention of Colon Cancer:
Colonoscopy, Virtual Colonoscopy, and DNA Stool Tests
Sheldon Lidofsky, MD
Colorectal cancer (CRC) is the
third leading cause of cancer and the
second leading cause of cancer mortality in the United States, responsible for
almost 150,000 cases and 57,000
deaths in 2003.1 Average-risk individuals have a 5%-6% lifetime risk of developing CRC.2 Survival is directly
related to the stage of cancer at the time
of diagnosis. The 5-year survival rate
is 92% with localized disease; less than
60% with spread through the bowel
wall; and 7% in the presence of distant metastases.2 There is strong evidence that population-based screening
can reduce the mortality from CRC by
detection of CRC at early stages.2
Progression from normal colonic
mucosa to adenomatous polyp, then
early invasive carcinoma into symptomatic CRC occurs over a period of
years.3 This orderly progression offers
an excellent opportunity to prevent
CRC through the detection and removal of adenomatous polyps, and to
decrease CRC mortality through its detection at early stages.
Evidence-based
guidelines
strongly recommend population-based
screening for CRC.2, 4, 5 This paper will
address the role of colonoscopy, and the
promising new tests of CT
colonography
or
“Virtual
colonoscopy,” and fecal DNA testing,
in screening for CRC.

COLONOSCOPY
Colonoscopy permits visualization
of the entire colon directly, detection
and removal of polyps, and biopsy of
CRC anywhere within the colon and
rectum. It requires adequate bowel
preparation using laxatives or large volumes of an oral cathartic solution. IV
sedation minimizes pain and discomfort. The endoscope is maneuvered
within the bowel and bowel distention
with air is required for adequate evaluation of the colonic mucosa. Most polyps can be removed by electrocautery
techniques.
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Almost 40% of CRC arise proximal to the splenic flexure.6 Studies in
patients with CRC proximal to the
splenic flexure have found that a least
two thirds of these patients have no
CRC or adenomatous polyp distal to
the splenic flexure.7, 8 The cecum is
reached in 80% to 95% of procedures.9
Incomplete colonoscopies require either a repeat colonoscopy or supplemental barium enema to clear the
proximal colon and cecum.
There are no studies evaluating
whether screening colonoscopy alone
reduces the incidence or mortality from
CRC in the average risk patient population.2 There is, however, considerable indirect evidence of this. Data
from the clinical trials of Fecal Occult
Blood Test (FOBT) screening demonstrated reduced CRC mortality, with
colonoscopy and polypectomy representing an integral part of the evaluation of a positive FOBT.10, 11 There is
direct evidence that screening sigmoidoscopy reduces CRC mortality.12, 13
These studies emphasize the effectiveness of endoscopy and polypectomy,
and can be extrapolated to establish the
effectiveness of colonoscopy with
polypectomy, which offers more complete examination of the colon.14 The
National Polyp Study demonstrated
that patients who had colonoscopy
with complete polypectomy had a 76%
to 90% reduction in the expected rates
of CRC over the subsequent 6 years
and there were no deaths from CRC.15
This reduction in expected rates and
mortality of CRC occurred in a population with adenomatous polyps, a
population at much higher risk for
developing CRC compared to a screening population.
Colonoscopy is often referred to
as the gold standard for the presence
or absence of polyps and CRC. 9
Colonoscopy, however, even in experienced hands, can miss lesions.
Hixson et al.16 evaluated the miss rate
of 2 colonoscopists by performing 2

consecutive same-day colonoscopies on
90 patients. They found a miss rate of
15% for polyps< 1 cm. and 0% for
polyps> 1 cm. Rex ct al.17 performed
2 consecutive same-day colonoscopies
on 183 patients. The overall miss rate
for adenomas was 24%, 27% for adenomas<5 mm, 13% for adenomas 69 mm, and 6% for adenomas > 1 cm.
Patients with 2 or more adenomas at
the first examination were more likely
than patients with no or 1 adenoma at
the first examination to have 1 or more
adenomas at the second examination.
Adenoma miss rates correlated
with withdrawal technique.18 Examinations of the proximal sides of flexures, folds, and valves; cleaning and
suctioning; adequate distention; and
adequate exam time were important
factors in achieving a lower
adenomatous miss rate.
In a recent study of CT
colonography (CTC), sensitivity and
specificity of colonoscopy were assessed.19 Same-day CTC and conventional colonoscopy were performed.
CTC was the initial test, and lesions
were reported for each segment of the
colon. Colonoscopy was then performed, the colonoscopist unaware of
the findings of CTC. After completing the exam of a given colonic segment by colonoscopy, the results of the
CTC for that segment were revealed,
referred to as segmental unblinding. If
CTC revealed pathology, but that pathology was not present on
colonoscopy, there was a second
colonoscopic examination of that segment performed. If pathology was
identified on the second examination,
the colonoscopy was considered a false
negative for that segment. The sensitivity of CTC for adenomatous polyps
was 93.8% for polyps> 1 cm, with 96%
specificity, compared to 87.5% sensitivity with colonoscopy. Most of the
clinically significant adenomas missed
prospectively on conventional
colonoscopy were located on a fold,

especially on the backside of a fold, or
near the anal verge.20
Colonoscopy is associated with the
greatest risk of complications among the
screening tests. Complications include
perforation, hemorrhage, respiratory
depression due to sedation, arrhythmias,
ileus and nosocomial infection. Approximately 1/1000 patients have perforation, 3/1000 have major
hemorrhage, and 1-3/10,000 die as a
result of the procedure.9 Serious disorders of sodium balance were reported
after use of a Polyethylene Glycol colon
preparation, including seizures and
death.21 Cases of hyponatremia with
encephalopathy have been reported after use of Visicol tablets.22, 23
Expert panels recommend that
colonoscopy screening be performed at
10-year intervals if the initial exam is
negative.2, 9, 18 This recommendation
is based on the dwell time from the
development of adenomatous polyps to
transformation into CRC, estimated to
be~10 years,15 and on a case control
study of screening rigid sigmoidoscopy
which found a protective effect from
death due to CRC for up to 10 years
in that segment of colon examined.12
However, the interval at which screening colonoscopy should be performed
in average-risk persons has not been determined by observational studies. The
longest reported interval between an
initial normal colonoscopy and a second colonoscopy in a group of asymptomatic average risk persons 50 or older
is 5.5 years.24 Cancer incidence in this
population was 0% at 5.5 years, and
the incidence of adenomas with advanced pathology, defined as those> 1
cm in size, or containing villous tissue
or high grade dysplasia, was <1%.
In a recent study by Schoen et al.25
6 of 1292 patients had CRC discovered in the distal colon 3 years after a
baseline sigmoidoscopy; 72 patients
had an advanced adenoma. Some of
these lesions were likely missed on the
baseline study because of the known
inherent miss rate of colonoscopy.
However, up to 15% of CRCs have
microsatellite instability, associated
with mutations of MMR genes. These
patients may develop polyps which
evolve more rapidly to CRC.26

Colonoscopy is one of the recommended screening tests for CRC for
persons age 50 and older who are at
average risk of developing CRC.2, 4 It
is the preferred screening test for persons age 50 and older who are at average risk for developing CRC as
recommended by the American College of Gastroenterology.14 It is the recommended screening test for people at
an increased risk for developing CRC,
including those with a family history
of CRC or adenomatous polyps.2,4,14
Surveillance with colonoscopy is
recommended for patients who are at
increased risk because they have a prior
history of CRC or prior adenomatous
polyps, or have a disease that predisposes them to CRC, such as inflammatory bowel disease.2, 4, 14
Colonoscopy has been found to be
cost-effective in comparison to other
CRC screening strategies.27

CT COLONGRAPHY
(CTC). OR “VIRTUAL
COLONOSCOPY’
CTC is a new, non-invasive
method for examining the colon. Its
non-invasiveness, speed of performance, lack of requirement for patient
sedation, and high predictive values
makes it attractive.28
The technique, as described by
Bruzzi et al.,28 involves the rapid acquisition of thin section CT slices of
the prepared colon using a helical CT
scanner, and the subsequent manipulation of data to produce 2 – Dimensional axial or 3 – Dimensional images
that resemble an endoscopic view of the
bowel lumen. Bowel cleansing regimens are commonly used. Residual
fecal material can result in both falsepositive and false-negative findings.
Fecal tagging methods allow CTC
evaluation in the setting of a minimally
prepared or unprepared colon. Fecal
tagging involves the administration of
small amounts of barium or watersoluble contrast material 1 day prior
to CTC. Fecal material is, therefore,
labeled with high- density contrast and
identified as such rather than as polyps or mass lesions.
Adequate colonic distention is required, accomplished by placement of

a soft-tipped enema tube within the
rectum, followed by air or CO2 insufflation to the maximal limit tolerated
by the patient. The patient is then
scanned in both the supine and prone
positions to redistribute the gas into
segments of the colon that may have
been collapsed.
Fenlon et al.29 studied 100 highrisk patients comparing CTC with
conventional colonoscopy. CTC detected 3 of 3 cancers and 20 of 22 polyps> 1cm, a 91% sensitivity. There
were 19 false- positives. Sensitivities
for polyps 6-9 mm and for polyps<
6mm were 82% and 55% respectively.
Pickhardt et al. 19 performed a
multicenter trial involving 1201 average risk patients who underwent same
day CTC and conventional
colonoscopy. Stool tagging and digital subtraction, 3-D endoluminal imaging, and segmental unblinding of
CTC results at colonoscopy, were performed. The sensitivity of CTC for
adenomatous polyps was 93.8% for
polyps at least 1 cm in diameter, 93.9%
for polyps at least 8 mm in diameter,
and 88.7% for polyps at least 6 mm in
diameter.
The sensitivity of
colonoscopy for adenomatous polyps
was 87.5%, 91.5%, and 92.3% for the
3 polyp sizes, respectively. Specificity
of CTC for adenomatous polyps was
96.0% for polyps at least 1cm, 92.2%
for polyps at least 8 mm, and 79.6%
for polyps at least 6mm in diameter.
Two polyps were malignant and both
were detected on CTC. One of those
malignant polyps was identified on
colonoscopy only after the results of
CTC were revealed on segmental
unblinding. As well, unsuspected
extracolonic malignancies were identified in 4.5% by CT findings.
Pickhardt et al. demonstrated that
CTC compared favorably to conventional colonoscopy in detecting
colorectal neoplasms in asymptomatic
average risk adults.
Cotton et al.30 performed a multicenter study of 615 predominantly average risk patients age 50 and older
referred for routine colonoscopy to assess the accuracy of CTC compared
with colonoscopy. There was no stool
tagging or use of 3-D rendering as a
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primary review.
Findings at
colonoscopy were reported before and
after segmental unblinding to the CTC
results. The sensitivity of CTC for
detecting patients with one or more
lesions at least 6 mm was 39%; for lesions at least 1 cm, it was 55%. This
was significantly lower when compared
to conventional colonoscopy, with sensitivities of 99% and 100%, respectively. CTC missed 2 of 8 CRCs.
There is, therefore, wide variability in the sensitivity and specificity of
CTC. Several factors contribute to this
inconsistency, as noted by Van Dam et
al.31 First, different technologies have
been used in various studies. The data
suggest that multi-detector scanners
allow more accurate detection of
smaller lesions than single slice scanners. Hardware and software used to
analyze images varies widely, as does
bowel preparation methods, and the
presence or absence of stool tagging.
Finally, there is variation in the study
populations’ relative risk for neoplasia
CTC potentially offers the advantage of identifying CR neoplasms that
may not be adequately identified by
conventional colonoscopy. It has the
capacity of imaging the colon proximal to obstructing lesions and it can
serve to complete examination of the
colon after an incomplete
colonoscopy.
Levin et al.32 described the limitations of CTC:
1) False positive readings in approximately15%
2) An unknown ability to detect
flat adenomas, which may be a
more aggressive from of neoplasia
than
the
typical
adenomatous polyp;
3) Lack of performance and training standards;
4) CTC is a diagnostic tool only,
with no capability of polyp removal during the procedure;
5) The concern for cumulative radiation doses with scrial screening examinations;
6) The cost of CTC may be higher
than that for conventional
colonoscopy.
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Van Dam et al.31 identified fundamental questions that remain unanswered. Is there a minimum polyp size
detectable by CTC for which patients
should be referred for endoscopic
polypectomy? What polyp size, if any,
can remain in situ and undergo CTC
surveillance rather that immediate
polypectomy?

FECAL DNA TESTING
Our understanding of the molecular biology of colorectal carcinogenesis
forms the basis for detecting CRC by
detection of different mutations in
DNA exfoliated into the stool. Neoplasm-specific DNA mutations are released into the bowel lumen
continuously via exfoliation, rather
than intermittently via bleeding. DNA
is stable in stool and amplification techniques, such as polymerase chain reaction allow its detection in minute
amounts. The stool analysis involves
the collection of an entire bowel movement. Dietary restrictions are not required before testing.
Sporadic CRC is divided into
those demonstrating chromosomal instability, and those with an impaired
mismatch repair (MMR) mechanism.33
CRCs with chromosomal instability are
characterized by the progressive accumulation of mutations in several genes,
including the tumor suppressor genes,
APC and k-Ras, and the p-53
oncogene. These constitute approximately 85% of sporadic CRCs.33 Both
pathways are associated with characteristic DNA alterations, which may be
detected in stool.
Since no single mutation has been
found that is expressed in all CRCs,
panels of various markers are required. 33 A commercially available
panel from EXACT Sciences Corporation includes 15 specific point mutations on APC, k-RAS, and p-53; gene
mutations on BAT-26, a marker of
microsatellite instability; and long
DNA, a marker of DNA not degraded
by apoptosis.32 If any component of
the panel is positive, the result is characterized as positive.
Four studies 34,35,36,37 have reported
using the multi-target assay panel.
Overall, 99 of the 146 patients with

CRC were successfully detected by
stool DNA analysis, a 67.8% sensitivity for CRC. A total of 240 patients
without colonoscopic abnormalities
demonstrated the presence of mutations in only 10, for a specificity of
95.8%. Brand et al.35 demonstrated no
advantage to more than 1 sample per
patient for stool DNA testing. Syngal
et al.37 analyzed fecal DNA from 56
patients whose CRCs had been diagnosed at colonoscopy. A 62% sensitivity for invasive cancer was reported.
Stools were also obtained following
surgical resection of the primary CRC.
By 6 months post- operatively, the previously found stool DNA mutations
were no longer detectable.
The results in these studies in patients with adenomas>1cm in size have
been quite variable, ranging from a
high of 73% 34 to a low of 27%.37
Dong, et al.38 were able to detect
the majority of CRCs by analyzing stool
DNA for just 3 genetic markers- p -53,
BAT -26, and k-Ras. 51 patients who
had CRC diagnosed at colonoscopy
were evaluated. Prior to surgery, stool
samples were collected and matched
with each patient’s tumor tissue. The
stool was analyzed for the 3 genetic
markers. Thirty patients demonstrated
p-53 gene mutations in tumor DNA,
and identical mutations were found in
their stools. In 3 patients, mutations
at the BAT-26 locus was identified in
tumor, and also in each of the patient’s
stools. Nineteen patients demonstrated
a k –Ras mutation in tumor tissue, identical to those detected in their stools.
In no case was a mutation found in the
stool that was not present in the primary tumor tissue.
The feasability of detecting APC
mutations in fecal DNA was studied,39
employing a novel assay called digital
protein truncation.Stool samples from
28 patients with non-metastatic CRCs,
18 patients with adenomas that were
at least 1 cm, and 28 control patients
without neoplasm were studied. APC
mutations were identified in 17 of the
28 patients with Duke’s stage B2 cancer (61%), 9 of the 18 patients with
adenomas at least 1 cm (50%), and in
none of the 28 control patients. They
concluded that APC mutations can be

detected in fecal DNA from patients with relatively early
CR tumor.
Traverso, et al.40 also demonstrated the ability of fecal
DNA to detect proximal CRC. Using a method for
microsatellite mutation detection, 18 of 46 proximal CRCs
had microsatellite alterations detected. The identical mutations were identified in the fecal DNA of 17 of these 18 cases,
with a zero% false positivity among 69 individuals with normal colonoscopies, or among 19 individuals with adenomas.
This demonstrates that DNA is not degraded as it passes
through the length of colon.
The American Cancer Society’s CRC Advisory Group
concluded that questions related to the most appropriate
markers for DNA detection of CRC, on the best combination of markers, and on the results of studies in populations
at average risk for CRC need to be answered before DNA
stool testing can be recommended as a screening test for the
average risk adult.32

CONCLUSION
The emerging competitive techniques to diagnostic
colonoscopy of CTC and fecal DNA testing, though promising and innovative technologies, at this time remain unproven
as screening options for the average risk population of adults
who are 50 or older. These technologies should be re-visited
in the near future as additional data become available.
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Colorectal Cancer Screening Resources
In Rhode Island
Arvin S. Glicksman, MD
There is essentially universal
agreement that timely and appropriate
colorectal screening can detect and remove precancerous polyps and/or detect colon cancer in an early, curative
stage. In a previous survey,1 the Rhode
Island Cancer Council found that there
was uniform agreement of the gastroenterologists and surgeons who perform endoscopy and the primary care
physicians that colonoscopy was the
preferred procedure for colorectal cancer screening (the gold standard). Currently, approximately 50% of the
population over the age of 50 have not
had any test for colorectal cancer whatsoever. Some concern was expressed
that if a major educational program
were to increase the number of individuals seeking colorectal cancer
screening, resources within the State
might be overwhelmed. Accordingly
the Rhode Island Cancer Council surveyed the endoscopists in the State,
seeking information on the capacity of
resources and their utilization. A second survey sought to determine the
length of time to schedule an endoscopy appointment.
Sixty-eight questionnaires were
sent to endoscopists in Rhode Island.
Forty-two (62%) were returned.
Ninety percent of the respondents ex-

perienced an increase in referrals/requests for colonoscopy in the last year.
They reported that 80% of the patients
are aware of their status as either a standard risk or being at high risk for colon cancer and they reported that 33%
of the procedures resulted in finding
some abnormality. (Table 1)
On average, the respondents reported performing 75 procedures per
month. They believed their practices
could accommodate approximately
twice the number that they are performing.
The respondents all performed
endoscopy examinations in a hospital
endoscopy suite. In addition, a third
of the endoscopists also utilized a dedicated freestanding endoscopy suite;
only 10% performed endoscopies in
their office suites. At no site did they
report that the demand exceeded the
capacity for performing colonoscopy.
On the basis of this data, an increase in the number of educational
programs to improve the number of
Rhode Islanders seeking this cancer
screening examination can move forward without concern of overwhelming our capacity. In fact, expansion of
endoscopy suites is planned at two
hospitals. The availability of time that
endoscopists can devote to

colonoscopy may be a limiting factor
in expanding the number of procedures
performed. Another limiting factor
may be the number of female
endoscopists since many women would
prefer being examined by a female
endoscopist. As in most other disciplines in Rhode Island, recruiting new
physicians remains a serious impediment to the delivery of health care. The
Rhode Island Cancer Council is investigating other barriers to patient participation in screening colonoscopy.
Since our data would indicate that
the State of Rhode Island currently has
adequate facilities for endoscopy, we
wished to determine how soon a procedure could be scheduled by an individual seeking referral to an
endoscopists. We contacted 68 individual endoscopy offices with the following scenarios:

SCENARIO A
A 63 year old woman with a family history of colon cancer (her father).
She has never had any procedure before. She went to the emergency room
because she thought she had the flu and
the emergency room physician, after
taking care of her acute problem, also
recommended to her that she should
seek an appointment for colonoscopy.

SCENARIO B
A 55 year old man who, on routine physical examination, was found
to have a positive fecal occult blood
test. He had never had a colonoscopy
before.

SCENARIO C
A 70 year old man in good health
with no family history of colon cancer, but was convinced by his children
that this was an important test that he
should have performed.
Scenario A results indicated that a
person calling could have a scheduled
colonoscopy within 1 month in 52%
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of the offices; within 2 months in 67% of the offices; and
within 3 months for 97% of the offices.
For Scenario B, 41% of the offices could schedule an
examination within a month and 52% of the offices would
schedule him within 6 weeks; 98% of the offices would
schedule him within 3 months.
For Scenario C, 78% of the offices could schedule an
examination within 1 month and 95% of the offices would
schedule an examination within 2 months.
On the basis of these surveys, Rhode Island currently
has adequate facilities for performing colonoscopy and individuals seeking this screening procedure would not experience an undue delay. (Table 2)
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PSA Screening
Steven Cohen, MD, Stephen Schiff, MD, and Patrick Kelty, MD
The PSA screening era was born
in the mid 1980’s.1,2 With the use of
PSA non-palpable prostate cancer
could be detected, thus, ultimately,
leading to the peak detection rates of
210,000 cases per year (SEER data of
1993-95). As we have exhausted the
“back-log” of undetected cancer we
have returned to the baseline prevalence of prostate cancer, detecting ,
once again, about 180,000 new cases/
year.
Unfortunately, PSA is prostate
specific not cancer specific. Recent
studies, such as MTOP’s work by John
McConnell and Claus Roehrborn et
al,1 and Tom Stamey2 have revealed that
PSA is most closely related to prostate
volume, not necessarily cancer. Additionally, in multivariate analyses used
to predict prognosis, Gleason sum (histologic grade) and stage of cancer is
more significant than PSA. These facts
raise questions whether prostate cancers found by biopsies are found because of elevated PSA or represent
clinically insignificant tumors found
randomly by biopsy. A recent New
England Journal of Medicine3 article
points out prostate cancer may exist in
men with low “normal PSA”. Therefore, correcting PSA for age-adjusted
values reflect more prostatic size and
PSA relationships (young men-small
prostates, older men-larger prostates).
This also allows us to be more aggressive in young men with low PSA where
diagnosis and treatment may alter life
expectancy compared to older men
who may not benefit from aggressive
therapy. Therefore “age-corrected”
PSA and not “ lab normal values”
should be utilized. The more we learn
about PSA, the more questions arise:
one thing remains true, PSA is still the
best biochemical tumor marker available today. It is far more reliable than
CEA and CA- 125. We must learn and
understand when to use and how to
apply PSA clinically.
The American Urological Association guidelines recommend prostate
cancer screening in men who have at
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least 10 years life expectancy, generally
between the age of 50-75. The “fear”
of legal repercussion of “failure to diagnose” is not a reason to screen men
for prostate cancer. Therefore, men
over 75 years old and men with less
than 10 years life expectancy should
not be screened. Early prostate cancer
detection is unwarranted, not cost-effective, may lead to harmful interventions and will not impact longevity,
High risk men (African-American and
those with hereditary or familial links)
should start screening at age 40.
Ever since the introduction of
PSA, efforts have focused on increasing the accuracy of the test in the context of early detection of prostate
cancer. Elaborated only from the ductal epithelial cells of the prostate, PSA
is an excellent tool for monitoring disease status following radical prostatectomy. Postoperatively, serum levels
should become undetectable unless
there is persistent or recurrent disease.
However, when PSA is used as a cancer screening tool with an intact prostate, the lack of specificity and
sensitivity hampers its effectiveness.
PSA values of up to 4.0 ng/ml
have been considered “normal;” however, recent studies have suggested 15%
of patients with so-called normal PSA
may have prostate cancer and a small
percentage of those may harbor high
grade disease. Consequently, there is
also interest in improving the sensitivity of the PSA test to reduce the prevalence of false negative tests.
PSA values in the 4 to 10 ng/ml
range are considered to be in the “grey
zone” with 60-75% of these men having negative biopsies. Refinements in
the PSA test will go a long way to improve the diagnostic accuracy for these
patients.
PSA is a protease and the proteolytic activity in the blood stream is
inhibited by the formation of complexes with serine protease inhibitors.
Most PSA is bound and only a small
portion is unbound, or “free.” Most
PSA
is
bound
to
ACT

(antichromtrypsin). It is widely accepted that in patients with prostate
cancer, more PSA is in the PSA-ACT
isoform and in healthy men with benign prostatic disease, there is a greater
proportion of fPSA (free PSA).
Many studies have demonstrated
improved specificity utilizing the ratio
of total to percentage free PSA, with
values of free PSA greater than 26%
more likely associated with benign disease. This calculated ratio is a useful
test to help reduce unnecessary biopsies after previous negative biopsies and
continued elevation of total PSA.
Recognizing that PSA complexed
with ACT is seen in a higher proportion of men with prostate cancer has
led to intense efforts to develop sensitive assays to detect PSA-ACT in an
effort to further increase the accuracy
of PSA testing. Some studies have
shown complexed PSA to be equivalent to total PSA while others have
shown it is better. However, technical
difficulties with cross reactivity and
questions about clinical usefulness remain.
There is great interest in improving the accuracy of PSA testing, which
could reduce the number of unnecessary biopsies and increase the predictive value of PSA. There is active
interest in the lower ranges of PSA in
an effort to maximize the detection of
prostate cancer. This lower range will
include many men without cancer and
the enhanced specificity of the
complexed PSA may allow those who
are truly cancer free to avoid biopsy.
Ongoing research continues to refine the role of PSA and its various
forms in an effort to improve the accuracy of prostate cancer early detection. Critics claim, with merit, that
this lack of specificity leads to many
unnecessary prostate biopsies. In a
patient with an abnormal PSA, cancer
is found in only 25-33% of cases. This
means that 67-75% of prostate biopsies are “unnecessary” since benign tissues are found.
Due to this lack of specificity, in-

vestigators have been trying to clarify
the use of PSA by using various modalities such as PSA velocity, PSA density, and free/total PSA ratios. None
of these various derivatives have decreased the number of negative prostate biopsies;i.e., the specificity of PSA
in differentiating benign disease from
cancer did not change significantly.
Despite its usefulness, there are serious
limitations in the use of PSA as a
screening tool. This has led to the
search for better tumor markers, which
are more specific for cancer while maintaining sensitivity.
One experimental marker is prostatic specific membrane antigen
(PSM). This is a protein located on
the plasm membrane that is expressed
higher in prostate cancer cells than in
benign cells. The use of PSM as a
marker has a sensitivity and specificity
of 58% and 47%, respectively. The
main drawback with this marker is that
it is found via RNA samples in the serum. It is detected via reverse transcriptase amplification. When used in
conjunction with PSA, it has not offered a greater specificity.5
Another marker being investigated
is alpha-methylacyl coenzyme A
racermase (AMACR). This protein is
expressed in higher amounts by prostate cancer cells. It can be found in
prostatic secretions and in the urine
after a prostate biopsy. The drawback
of this marker is that it was found in
the urine of patients who had just recently had a prostate biopsy; however,
86% of men with prostate cancer on
biopsy did express AMACR in their
urine. Thus, this marker would not
decrease the amount of initial negative
prostate biopsies. One potential use
for this marker may be to stratify patients with initial negative prostate biopsy in the face of a rising PSA. At
this point, many of these patients require repeat prostate biopsies. The use
of AMACR in the voided urine after
the initial biopsy may help determine
who truly has benign disease and who
has a greater chance of having a malignancy and needs a repeat biopsy. 6
One of the more interesting and
promising approaches is the use of artificial intelligence (AI) and neuronal

networks in the screening of prostate
cancer. In the most recent study, investigators analyzed serum proteomic
streams generated by high resolution
mass spectroscopy by using a pattern
recognition algorithm. After initial
training of the pattern recognition program, the serum samples of men with
PSA in the 2.5-15 range were examined to try and differentiate between
cancer and benign disease. The model
used in this study yielded a sensitivity
of 100% and a specificity of 67%.
What this means is that the use of this
method would obviate the need for
prostate biopsies in 67% of men with
elevated PSAs, while no cancers would
have been missed. Further testing is
needed to determine if this data can
be reproduced, but this is certainly one
of the more promising methods to increase the specificity of prostate cancer screening.

…men over 75
years old and
men with less
than 10 years
life expectancy
should not be
screened.
Despite a decrease in prostate cancer deaths since the use of PSA, the
screening for prostate cancer remains
controversial. The use of PSA and how
to properly use it is at the center of this
controversy. Although it remains the
most sensitive and useful tumor marker
available today, it has limitations, particularly in its lack of sensitivity. The
use of various PSA derivatives and the
search for newer tumor markers have
had mixed results, which further fuels
this controversy. Future efforts in redefining the role of PSA in benign and
malignant disease, the use of newer
markers, and the use of intelligent technology will, we hope, decrease the unnecessary biopsies and the controversies
surrounding the screening for prostate
cancer.

REFERENCES
1. McConnell JD, Roehrborn CG, et al.
The long-term effect of devazosin
finasteride and combination therapy
on the clinical progression of benign
prostatic hyperplasia, NEJM 2003;
349:2387-98.
2. Stamey TA, Yang N, et al. Prostate
specific antigen as a serum marker for
adenocarcinoma of the prostate.
NEJM 1987; 317:909-16.
3. Thompson IM, Pavler DR, et al.
Prevalence of preventative prostate
cancer among men with a prostatespecific antigen level. NEJM 2004;
35:2239-46.
4. Kuriyama M, Wang MC, et al. Use of
human prostate specific antigen in
monitoring prostate cancer. Cancer Res
1981;41:3874-6.
5. Schmittgen TD, Teske S, et al. Expression of prostate specific membrane antigen and three alternatively spliced
variants of PSMA in prostate cancer patients. Int J Cancer 2003;107:323-9.
6. Rogers CG, Yan G, et al. Prostate cancer detection on urinalysis for
[alpha]methylacyl coenzyme a racemase
protein. J Urol 2004; 172:1501-3.

Steven Cohen, MD, is Clinical Assistant Professor of Surgery (Urology),
Brown Medical School.
Stephen Schiff, MD, is Clinical Assistant Professor of Surgery (Urology),
Brown Medical School.
Patrick Kelty, MD, is Clinical Instructor of Surgery (Urology), Brown
Medical School.

CORRESPONDENCE:
Steven Cohen, MD
Urologic Surgeons of New England, Inc.
125 Corliss St.
Providence, RI 02904
Phone: (401) 274-6565
Fax: (401) 331-2370

91
Vol. 88 No. 3 March 2005

Skin Cancer Prevention and Detection—
melanoma and beyond
Katharine B. Cordova, MD, and Martin A. Weinstock, MD, PhD
Skin cancers are the most common malignancy in humans.1 Despite
recent educational campaigns and advances in medical knowledge, the incidence of keratinocyte carcinomas
(KC) and melanoma continues to increase. KC refers to basal cell carcinoma (BCC) and squamous cell
carcinoma (SCC), the two most common types of skin cancer. BCCs and
SCCs arise from keratinocytes and occur with a relative frequency of 4:1.2
KCs rarely metastasize and can generally be cured with outpatient procedures. However, if left untreated these
tumors can cause significant disfigurement, local destruction, and sometimes, but not often, death. National
reporting of KC is imprecise, but the
most recent figures from the American
Cancer Society estimate over one million cases will be diagnosed this year.3
Melanoma is the most serious
form of skin cancer. Of all reported
cancers in the United States, melanoma
ranks fifth and seventh in incidence
among men and women respectively.
The incidence continues to rise and an
estimated 55,100 new cases will be diagnosed in 2004 with 280 in Rhode
Island.3 Approximately half of all melanomas affect people younger then 55
years of age and deaths from melanoma occur at a younger age then most
other cancers.4 Although the mortality rates for melanoma have stabilized
in recent years, an estimated 7,910
people will die from the disease in
2004.3
A combination of inherent host
factors and exogenous environmental
influences interact to develop these
malignancies. Patients with more then
a hundred nevi, atypical nevi, congenital nevi, a personal or family history of
melanoma, or a personal history of KC
are at greater risk for melanoma development. Fair skinned individuals with
light eyes and poor tanning ability are
more likely to develop skin cancer then
their dark skinned counterparts. How-
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ever, African Americans are more likely
to die from the disease once diagnosed.
3
Additionally, rare genetic syndromes
that impair the body’s ability to repair
UV-damaged DNA are associated with
early and severe onset of melanoma and
KCs.
Sun exposure is the major modifiable environmental factor for all types
of skin cancer. In addition to overall
quantity, the pattern and timing of UV
exposure also appears relevant.
Whereas the most common variants of
melanoma are associated with intermittent, intense periods of UV exposure,
SCC development seems to reflect a
more chronic, cumulative exposure
pattern. Reports on BCC are mixed,
with some reporting intermittent
rather than cumulative sun exposure to
be more influential.5 Childhood exposure and sunburns seem particular
important. People with five or more
severe sunburns in childhood are estimated to be at twofold greater risk of
developing melanoma.6 Higher rates
of melanoma are also found in people
living (or who have spent their childhood) near the equator where UV exposure is the most intense. Artificial
sources of ultraviolet radiation such as
tanning beds and UVA with psoralen
have also been associated with increased melanoma and KC development.7,8
Additional environmental risk factors for KC include exposure to ionizing radiation or certain chemicals,
chronic immunosuppression, smoking,
arsenic ingestion, and chronic oral corticosteroid use. Transplant and immunosuppressed patients are at
particularly high risk for SCC development. SCCs in transplant recipients
develop earlier and are more aggressive;
these patients should be closely followed by dermatologists.

DETECTION
“WHAT ABOUT THIS SPOT”
Many patients present with con-

cerns about a new “bump” or “spot.”
Obtaining a focused history about the
presentation, evolution, and symptomatology of lesions may assist with
diagnosis and clinical decision-making.
Reviewing past medical history with
emphasis on personal and family history of skin cancer, evaluating for immunosuppression, and examining for
nevi, helps to stratify patients into relatively high or low risk categories.
KERATINOCYTE CARCINOMAS
Of all skin cancers, BCCs are the
most common. The majority (80%)
occur on the head and neck with the
remainder primarily found on the legs
and trunk.9 BCCs are subcategorized
according to clinical morphology and
histopathologic findings into nodular,
superficial,
pigmented,
or
morpheaform varieties.
The classic, nodular variety has a
characteristic morphology that is relatively easy to identify and diagnose on
presentation: it may be a “pearly” papule, often with translucent stroma, and
it may present with a rolled border,
central crust, and/or telangiectasia.
There may be a history of spontaneous bleeding of the lesion. Although
slow growing, the potential for local
destruction is significant if left untreated, especially when located near
eyes, ears, nose and lips. Incidence
increases with advancing age.
Superficial BCCs resemble eczema
or a local area of irritation, but have
more distinct margins and upon close
examination, pinpoint erosions may be
appreciated. They are typically on the
trunk and are slow growing tumors.
Pigmented BCCs may have a speckled
or more diffuse pigmentation, but also
may contain areas of pink or waxy skin.
Their clinical presentation can resemble melanoma.
The most aggressive form of BCC
is the morpheaform or sclerosing variety. These tumors account for 5% of
all BCCs and often resemble a scar or

area of sclerosis with ill-defined borders.9 Sub-clinical infiltration is common and these patients are often
referred to a Mohs surgeon to ensure
clear margins and minimize recurrence
potential.
SCCs, although readily visible,
may present a diagnostic challenge and
frequently need biopsy confirmation.
They present as a pink to red papule
often with an overlying crust or scale
and varying degrees of induration.
These lesions may arise de novo or develop from precancerous pink lesions
with adherent scale termed actinic
keratoses. In addition to sun exposed
areas, SCCs also develop in chronic
scars, prior burn sites, ulcers, sinus
drainage tracts, or mucous membranes.
SCCs in these less common locations,
as well as large, deep, or high grade
varieties have a greater propensity to
metastasize. The lip, ear, and genitalia
are also high risk sites for SCC. SCCs
account for the majority of deaths from
nonmelanoma skin cancer.10
PIGMENTED LESIONS
Melanomas are sub-classified according to clinical and histological features. The typical nodular melanoma
is a brown, black, or pink papule or
nodule. Superficial spreading melanoma, the most common form of
melanoma, is typically a flat or minimally elevated irregularly pigmented
lesion that grows radially prior to developing a vertical growth pattern.
Lentigo maligna melanoma most commonly presents as an asymptomatic
brown or black macule with irregular
borders and is classically seen on the
chronically sun exposed skin of the elderly. Acral-lentiginous melanoma typically appears as a tan to darkly
pigmented lesion on the fingers, palms,
or soles. This is the most common
form of melanoma seen in dark
skinned individuals and is often detected in a more advanced stage.
Given the considerable variation
in clinical presentation, evaluation of
pigmented lesions can be daunting.
Many benign, pigmented lesions can
mimic melanoma and distinguishing
the harmless from the harmful can be
difficult for even the most practiced

eye. Thus, treating physicians typically
maintain a low threshold for biopsy.
As a result, a significant number of
benign lesions are removed or sampled.
This cautious approach recognizes that
the most important prognostic indicator of all melanomas is depth of invasion at time of diagnosis. Melanomas
less than 1 mm in thickness have an
estimated ten-year survival rate of 8896%.11,12 As the depth increases, the
survival rates drop precipitously. Maintaining a high level of clinical suspicion aims to reduce mortality by
detecting and removing melanoma at
an early, curable stage; complete removal of in situ lesions and many other
early lesions is both treatment and cure.

Many benign,
pigmented
lesions can mimic
melanoma and
distinguishing
the harmless
from the
harmful can be
difficult for
even the most
practiced eye.
The ABCD rule is frequently used
by physicians and taught to patients to
help recognize potentially malignant
lesions. Identifying asymmetry, irregular borders, color variation, or diameter greater then 6mm should raise
clinical suspicion. However, studies
evaluating the ABCD guidelines report
a sensitivity of only 65-80%. 13,14
Therefore, many clinicians have advocated the “new or changing mole” message as an easier, more inclusive tool
for early melanoma identification.15 A
patient friendly booklet from the
American Cancer Society entitled
“Why you should know about melanoma” (American Cancer Society,
2004) emphasizes that a change in size,
shape, or color of spots on the skin is

the most important warning sign. By
using a more general, easy-to-remember message there is hope for greater
patient awareness and earlier detection
of melanoma.
In recent years, many dermatologists have adopted dermoscopy as an
additional diagnostic tool. By magnifying and viewing the lesion with polarized light or with liquid interface on
the skin surface, hand-held devices allow visualization of morphological features not apparent to the naked eye. For
physicians with formal training, use of
dermoscopy reduces the number of lesions submitted for biopsy and improves
clinical accuracy.16-18 Use of this tool
by untrained or inexperienced examiners, however, is not effective.18
SKIN CANCER SCREENING
Many patients see dermatologists
for routine skin checks. This probably
reflects a combination of factors: public health campaigns have raised awareness about skin cancer, time restraints
limit patient-doctor interactions to the
most pressing issues, and the fragmentation of healthcare provision amongst
specialists forces many patients to see
a different doctor for each aspect of
their healthcare. In patients considered to be high risk for melanoma, routine screening by dermatologists may
result in earlier detection and excision
of melanomas.19-21 However, most
melanomas do not occur in high-risk
individuals; therefore; early detection
efforts must be extended to the general population.22
Because the majority of the population visits a primary care clinician at
least every two years, these clinicians
are ideally suited to teach patients
about skin cancer and perform initial
screenings.23 Despite evidence that
physicians believe all patients should
be counseled about sun protection
strategies and confirmation that these
interactions positively impact patients’
skin cancer prevention practices, the
rate at which physicians counsel about
skin cancer prevention methods is quite
low (e.g. 29% sunscreen, 6% other sun
protection measures).24,25 In addition
to time constraints, primary care physicians have cited lack of confidence as
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a significant barrier to the practice of
skin cancer screening and prevention
counseling. This suggests that continuing medical education programs may
prove valuable. Even a brief (2-hour)
seminar teaching clinicians an 8-step
algorithm to triage patients with skin
lesions into categories of “Act,” “Reassure,” or “Track” was found to improve
their confidence, skills, and practices.26
In addition to physicians, patients
and their families are encouraged to be
active, engaged participants in their own
care. Teaching and promoting performance of monthly self-skin examinations has become more frequent in
dermatology practices. This is especially
aimed toward individuals with risk factors for melanoma development. Although a case-control study suggested
monthly self-skin exams could reduce
melanoma mortality by 63%, few patients perform these exams in a deliberate, systematic manner.27-29 Factors
found to be key predictors of performing thorough self-skin exams included
partner participation, access to a wall
mirror, and a recommendation by a
physician to do so.29
One constraint on both research and
advocacy efforts is the limited evidence
of efficacy and effectiveness of routine
thorough self-skin exams. Although supported by the American Cancer Society,
American Academy of Dermatology, and
Skin Cancer Foundation, the US Preventative Services Task Force finds insufficient evidence to advocate for self-skin
examinations. However the relative costs
of encouraging healthy self-assessment
practices seem few.22
Regardless of who is examining the
skin, a methodical approach is key. Establishing a consistent order of examination enables detection of subtle lesions
and ensures complete review of the entire skin surface. Controlling environmental factors such as lighting, patient
positioning, and removal of clothing also
promotes effective, thorough exams.
A recent review of KC associated
deaths in Rhode Island found over half
of them to be related to genital carcinoma. While men are more likely to
die from non-genital SCC, in women
the ratio was reversed: women were
three times more likely than men to die
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from genital skin cancer.30 Although
presence of pre-existing HPV infection
was not documented in every case, the
oncogenic potential of this virus is well
established. These findings reinforce the
need for physicians to examine genital
skin and to educate patients about HPV
transmission and infection.

PREVENTION
Skin cancer prevention efforts are
largely directed toward modifiable risk
factors; UV radiation exposure is the
most significant. Accordingly, the
American Cancer Society Goals and
Objectives for 2015 aims to have 75%
of people regularly using at least two
sun-sensible measures, such as liberal
use of sunscreen and wearing tightly
woven clothing and hats.3
Patients must be educated about
the importance of reducing intense UV
exposure for themselves and their children. Routine well-child visits provide
a forum to reach parents and their children before significant sun exposure
occurs. Childhood sun exposure is a
known risk factor for melanoma. By
establishing preventative behavior patterns during the formative years, skin
cancer can be prevented in current and
potentially, future generations.
Although the value of sunscreen
has been debated in the literature, regular use of sunscreen, especially in fair
skinned individuals, is considered to be
protective. As much as a 78% reduction in lifetime incidence of KCs has
been proposed to result from regular
use of sunscreen (SPF > 15) during the
first 18 years of life.31 Even in older
individuals with a history of significant
exposure, regular sunscreen use can
prevent development of new actinic
keratoses and hasten resolution of old
lesions. The protective effect of sunscreen on melanoma development is
less clearly delineated. However, considerable evidence suggests that by
blocking UV absorption and diminishing total UV exposure, sunscreen can
prevent melanoma formation as well.
When addressing sunscreen, most
dermatologists recommend products
that provide both UVA and UVB protection with an SPF of at least 30. Patients must be instructed to reapply

frequently (every 2-3 hours) and use
this as part of a general sun protective
approach. Sunscreens should not be
used to lengthen time in the sun.
Frequent reminders about skin
protection and detection practices are
a critical component of this public
health campaign; informed patients are
more likely to use sun protection measures and to bring suspicious lesions to
the attention of a physician.32

CONCLUSION
The public health impact of skin
cancer is enormous and increasing.
Sun-sensible measures need to be
taught and encouraged for all ages.
Early detection is essential to limit the
morbidity and mortality associated
with these tumors. The unique ability
to visually detect these lesions enables
the patient to take a more active role
in early cancer detection by performing skin self-exams. Given the huge
number of people affected, it is essential for primary care clinicians to be
active participants in patient education
and skin cancer detection.

RESOURCES
The American Cancer Society
(www.cancer.org, 1-800-ACS-2345),
the American Academy of Dermatology (www.aad.org), and The Skin Cancer Foundation (www.skincancer.org,
1-800-SKIN-490) are national organizations with information on skin cancer available for physicians and the
general public. Locally, there is a Mole
Mapping Program, designed for early
detection of melanoma in high-risk
individuals, at the Pigmented Lesion
Unit (444-7959) located at the Rhode
Island Hospital campus, as well as a
Multidisciplinary Melanoma Program
(444-8852) designed for patients who
are newly diagnosed with melanoma.
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Figure 1a.

Figure 1b.

Figure 1c.

Carotid Artery Stenting using Distal Embolic Protection Device
A 64-year-old female with a right pulmonary mass (1.2cm) for planned surgical resection was noted to have a left
carotid bruit on physical exam. Ultrasound and MRI exams showed 90% stenosis of the left internal carotid artery (ICA)
origin and less than 50% stenosis of the right ICA. The patient was asymptomatic from a carotid standpoint. She was
considered a high surgical risk for carotid endartectomy (CEA) due to a history of previous thyroid and cardiac surgery.
Following consultation with Interventional Radiology the decision was made to pursue percutaneous left carotid treatment
prior to lung surgery.
Carotid angiography confirmed high-grade stenosis of the left ICA (1a). The stenosis was crossed and the Accunet™
embolic protection device (Guidant Corp., Indianapolis, IN) was deployed above the stenosis to minimize risk of cerebral
embolization (1b black arrow). An Acculink™ stent (Guidant Corp, Indianapolis, IN) was then deployed across the
stenosis and dilated. (1b white arrow) Post deployment arteriogram confirmed no significant residual stenosis (1c). No
significant complications occurred post procedure and the patient was discharged home on Plavix and ASA.

DISCUSSION
Percutaneous treatment of carotid artery stenosis was first described in 1980. 1 Advances in stent design and the
addition of Embolic protection devices have made the procedure safer. Carotid Artery Stenting (CAS) now represents an
alternative to CEA, especially for high-risk patients. The worldwide technical success rate of CAS is 98.4 %.2 The thirtyday minor /major stoke rates are 2.72% /1.49%, 30-day mortality rate is 0.86% and six and 12-month restenosis rates are
1.99% and 3.46%.2

– NADIR KHAN, MD, TIMOTHY P. MURPHY MD, GREGORY J. DUBEL, MD
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Hospitalizations For Ambulatory Care Sensitive
Conditions
Karen A. Williams, MPH, and Jay S. Buechner, PhD
Hospital inpatient care is utilized to treat the most severe
conditions of disease, illness and injury. With appropriate
ambulatory care, some hospitalizations for certain conditions,
called ambulatory care sensitive conditions (ACSCs), are believed to be avoidable. Taken together, ACSC hospitalizations were estimated to account for 3.1 million hospitalizations
nationwide, representing 12% of all hospitalizations in 1990.1
Selected results from an analysis of the burden of ACSC hospitalizations in Rhode Island are presented here.

Methods

Acute-care hospitals in Rhode Island have been reporting patient-level data for every patient discharged since October 1, 1989, as required by licensure regulations. The data
items reported for each patient include demographics and clinical data coded to the International Classification of Diseases,
9th Revision, Clinical Modification (ICD-9-CM).2
Consistent with reports produced by the state of Massachusetts based on conditions originally compiled by Billings,
this analysis examined discharges with any of 24 conditions
defined as ACSC.3, 4, 5 (Table 1) Specific definitions of the
ACSCs are available upon request.
Hospitalizations for ACSCs cannot be avoided in all instances. The extent to which these hospitalizations are preventable varies by condition, general health status and other
factors. In this analysis, “self-pay” as the expected source of
payment was used as a proxy for uninsured. This analysis is
limited to Rhode Island residents discharged from Rhode Island hospitals during 2001- 2003, excluding newborn infants.

among those ages 18 – 34 to 1.3 percentage points for those
age 65 and older. (Figure 1) For all ages combined, the percentage of ACSC discharges was greater for the insured than
the uninsured; this anomaly is due to the different age distributions of the insured and uninsured populations.
The most common specific ACSCs among discharges
during 2001-2003 varied by age, with congestive heart failure,
bacterial pneumonia and chronic obstructive pulmonary diseases ranked highest overall and together accounting for over
half (55%) of all ACSCs. (Table 3) Bacterial pneumonia was a
leading condition for all age groups, while asthma ranked highest
among the younger age groups only. The most common ACSCs
also varied by insurance status. Most notably, diabetes, celluli-

Results

On average, more than 19,000 ACSC hospitalizations
occur each year, representing 17% of all discharges among
Rhode Island residents and accounting for 12% of the total
billed charges for inpatient care. (Table 2) Of the 57,749
ACSC discharges during 2001-03, 1,839 (3.2%) were uninsured.
ACSC discharges as a percent of total discharges increased
with age, with the exception of the 0-17 years age group, whose
proportion was almost as great as in the oldest age group. (Table
2) For the two extreme age groups, almost one quarter of all
hospitalization are for ACSCs.
The percent of ACSC hospitalizations for patients without insurance was greater than for patients with insurance for
all age groups. The difference between the two populations
decreased with age and ranged from 8.8 percentage points
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tis and asthma were leading conditions
for the uninsured population overall, but
ranked much lower for the insured population.

Discussion

Figure 1. Discharges for Ambulatory Care Sensitive Conditions as Percent
of All Discharges, by Age Group and Insurance Status, Rhode Island
Residents, 2001 – 2003.

Hospitalizations for ACSCs comprise a large proportion of all inpatient
care in Rhode Island, both among the
insured and uninsured populations, and
they account for an even greater proportion among those who are young and uninsured. The most commonly occurring
specific ACSCs are different for patients
of different age groups and for patients
with and without health care coverage.
The rate of hospitalizations for
ACSCs has been suggested as an indicator of the access to and the quality of the
ambulatory care system serving the populations from which these inpatient discharges are drawn.1 On that basis, this
analysis demonstrates that many of the
uninsured may lack access to high quality ambulatory care. Further analysis,
e.g., by geographic area, by specific type
of health care coverage, by socioeconomic
status, by gender, by race and ethnicity,
etc., may help identify other specific
populations in Rhode Island with less
than optimal ambulatory care.
Additionally, the overall volume of
hospitalizations for ACSCs represents,
in whole or part, a potentially avoidable burden on the state’s health care
system. Eliminating even a portion of
these hospitalizations could free substantial resources for other health care
services or even reduce the costs of
health care coverage to employers, governments, and individual subscribers.
These benefits would accrue in addition to the health benefits to those
whose medical conditions were treated
or controlled before progressing to a
level of severity requiring hospital inpatient care.
Karen A. Williams, MPH, is Public
Health Epidemiologist, Office of Health
Statistics, Rhode Island Department of
Health.
Jay S. Buechner, PhD, is Chief, Office of Health Statistics, and Clinical Assistant Professor of Community Health,
Brown Medical School.
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Advances in Pharmacology
Can Robitussin® DM Be Used To Treat Cough
During Pregnancy?
Kristina E. Ward, PharmD
During cough and cold season, the question of whether
Robitussin® DM is safe for use during pregnancy often
arises. Robitussin® DM is available generically and contains guaifenesin (100 mg/5 mL) and dextromethorphan
(10 mg/5 mL). Because both dextromethorphan and
guaifenesin were marketed prior to the requirement for
pregnancy information in labeling, a pregnancy category
was not assigned to either ingredient; however, there is information available in the literature about the use of the
individual ingredients during pregnancy.

DEXTROMETHORPHAN
Dextromethorphan is the antitussive component of the
combination and is a derivative of morphinan, a structural
analog of codeine.1,2 Use of the d-isomer avoids the addictive and analgesic properties present in the l-isomer and
other codeine derivatives. Compared with codeine, the antitussive potency of dextromethorphan is nearly similar.3,4
Dextromethorphan acts centrally in the medulla oblongata
to raise the cough threshold and is also known to act as an
antagonist at N-methyl-D-aspartate (NMDA) receptors;
however, it is unclear whether its NMDA activity contributes to the antitussive effect since codeine does not bind to
NMDA receptors.1,5 Dextromethorphan is rapidly absorbed
from the gastrointestinal (GI) tract with onset of cough
suppression within 15 to 30 minutes and duration of effect
between five to six hours.1,2 Metabolism occurs in the liver
via cytochrome P450 2D6 forming two inactive metabolites and one active metabolite. Cytochrome P450 2D6
activity may be increased during pregnancy potentially causing alterations in clearance of medications metabolized
through this pathway, including dextromethorphan.6
A controversial animal reproduction study injected
dextromethorphan into chick embryos consecutively for
three days.7 At the highest dose, increases in congenital
anomalies (e.g., spinal and craniofacial defects) were observed. However, the findings were heavily criticized. The

findings were not replicated in rats or rabbits at doses up to
100 times the human therapeutic dose.8 Dextromethorphan
has a molecular weight of 271 daltons which is small enough
to be transferred to the fetus.9 However, data from two
surveillance studies of women who had taken
dextromethorphan during the first trimester, one being the
Collaborative Perinatal Project, found no relationship between the use of dextromethorphan and the incidence of
congenital malformations.10,11 Additionally, two recent casecontrol studies also found no evidence of increased risk of
congenital malformations with dextromethorphan use during the first trimester.12,13

GUAIFENESIN
Guaifenesin is an expectorant with no antitussive effect. Although guaifenesin’s mechanism of action is not completely known, it increases the volume and decreases the
viscosity of respiratory tract secretions. 14,15 Guaifenesin is
well-absorbed from the GI tract with approximately 60%
of guaifenesin hydrolyzed in the blood.14
Peer-reviewed evidence supporting the effectiveness of
guaifenesin as an expectorant is limited.15 One study evaluating the effectiveness of guaifenesin in patients with bronchitis found it ineffective.16 A second study in patients with
colds found that guaifenesin subjectively thinned mucus;
however, the guaifenesin treatment dose was two times the
recommended dose.17
Table 1. Dextromethorphan-Only Cough
Suppressants
Brand Name

Dosage Form

Strength

Delsym®

Suspension,

30 mg/5 mL
extended release

Lozenge

5 mg/lozenge

Lozenge

5 mg/lozenge

Hold® DM
®

Robitussin
Cough Calmers
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Guaifenesin has a molecular weight of 198 daltons,
indicating possible placental transfer. Data from three surveillance studies regarding the use of guaifenesin during
the first trimester is available.9-11 An increase in the risk of
inguinal hernias was noted with the first trimester use of
guaifenesin in 197 mother-child pairs during the Collaborative Perinatal Project.4 However, when analyzed for
guaifenesin exposure anytime during pregnancy this association was not significant. Two other surveillance studies
assessing 241 and 141 newborns whose mothers ingested
guaifenesin during the first trimester found no associations
between guaifenesin use and congenital defects.9,11
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CONCLUSION
The use of dextromethorphan for cough during pregnancy does not appear to produce an increased risk of congenital malformations in newborns. Similar data with
guaifenesin also suggests it is safe to use during pregnancy.
However, in general, the use of drugs should be minimized
whenever possible during pregnancy. Because the efficacy
data supporting the use of guaifenesin as an expectorant is
scant, the use of a dextromethorphan-only cough suppressant (see Table 1) should be considered. Additionally, patients should be advised to avoid cough preparations that
contain alcohol.
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11.
12.

NEW DRUG INFORMATION SERVICES
13.

The University of Rhode Island College of
Pharmacy would like to announce the development of Drug Information Services. This
service has a dual mission: to provide practitioners with timely, evidence-based information
and to serve as a training site for University of
Rhode Island Doctor of Pharmacy students and
post-doctoral residents. The Drug Information
Services will research drug-related questions
from practitioners, using the extensive resource collections at the Drug Information Services Library in Fogarty Hall, the University of
Rhode Island Library, and the Higher Education Library Information Network (HELIN).
Drug Information Services can answer diverse questions including (but not limited to):
drug-drug interactions, dosing in renal or hepatic impairment, drug use in pregnancy and
lactation, adverse effects of drugs, dosage and
administration, appropriate dosing and administration, and foreign drugs.
Call Drug Information Services Monday
through Friday, 8:30AM to 5PM at (401) 8749188.
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The Rhode Island Smokefree Public Place and
Workplace Law: Estimated Impact on Asthma
in the Rhode Island Workforce
Colleen Caron, PhD, Annie Gjelsvik, PhD, Elizabeth Harvey, MA, MS
Two distinguishing features set health legislation apart
from other public health interventions. First, health legislation has far reaching effects on population health by impacting large societal segments. Second, its impact is
sustained for the life of the legislation. In contrast, one-onone health interventions or small-scale health campaigns
marked by definitive start and end points risk message loss
within a message-inundated society.
Under recently enacted Rhode Island state law, workplaces are now smoke-free environments (Public Health &
Safety Act of 2004 - Smokefree Public Place and Workplace Law, Chapter 23-20.10).1 With few exceptions, employees are guaranteed a workplace environment free of the
prolonged and harmful effects of second-hand smoke (SHS)
exposure. The adverse effects of SHS include respiratory
effects such as asthma, emphysema, and lung cancer, and
cardiovascular effects such as heart attack and stroke. Seven
states have enacted smoke-free workplace or public place
smoke-free laws.2
SHS is known to trigger asthma symptoms, and is also
clearly implicated in the initial development of asthma.3
Research demonstrates that 8% of adult-onset asthma
(asthma diagnosed at ages 18 and above) is attributed to
SHS.4 SHS workplace legislation has a dual public health
benefit specific to individuals with asthma. First, it reduces
the risk of asthma exacerbations for employees with asthma,
thus expanding employment opportunities for those with
asthma. Second, it has the potential to reduce the development of adult-onset asthma, including work-induced adultonset asthma. Estimating the magnitude of these two public
health benefits is the focus of this paper.
Asthma is a leading chronic disease in the United States,
affecting 11% of adults 18 and older (2002), 5 including
an estimated 13% of Rhode Island adults ages 18-64 who
report ever having had asthma (diagnosed by a medical
provider, i.e., “lifetime asthma”). A smaller group, slightly
more than 8% of Rhode Islanders ages 18-64 in 2002, report having asthma at the present time (diagnosed by a
medical provider, i.e., “current asthma”).5
Estimates of adult-onset asthma attributed to the workplace vary greatly. Some studies attribute 10 to 15% of
adult-onset asthma cases to workplace exposures, while others place the estimate between 2 and 26%.6,7 Work-related
asthma is classified as one of two types, work-aggravated

asthma and new-onset or work-induced asthma.7 Work-aggravated asthma is defined as previously-diagnosed asthma
with an exacerbation of symptoms after exposure to substances in the workplace.7 New-onset asthma is defined as
newly-diagnosed asthma developed after exposures to substances in the workplace. “Newly diagnosed” is defined as
“never diagnosed with asthma” or “previously diagnosed and
symptom free for two years.”7 SHS exposure in the workplace is a potential cause of both work-aggravated asthma
and new-onset or work-induced asthma.4

METHODS
The public health impact of the “Public Health & Safety
Act of 2004” was assessed using data from the Rhode Island
Behavioral Risk Factor Surveillance System (BRFSS) collected in calendar year 2002 and from statistics published
by the United States Department of Labor, Bureau of Labor
Statistics, for the year 2002. The BRFSS conducts a national
telephone survey of randomly selected non-institutionalized
adults (ages 18 and older) who live in households with telephones, monitoring the prevalence of behavioral risk factors for leading causes of disease and death. The 2002 BRFSS
survey contained sufficient asthma-related questions to estimate asthma prevalence among Rhode Island adults, ages
18-64, traditionally the group of focus for workforce statistics in the United States. Data from the United States Bureau of Labor statistics were used to determine the number
of individuals in the Rhode Island workforce.

RESULTS
Lifetime Asthma
In 2002, a total of 468,451 persons were employed in
Rhode Island private industry and government combined.8
In the same year, an estimated 13% of employed Rhode
Island adults ages 18-64 reported lifetime asthma in response
to BRFSS survey questions.5 Therefore, an estimated 60,900
adults employed in Rhode Island in 2002 had lifetime
asthma. (468,451 employed persons times 13% of employed
adults ages 18-64 with lifetime asthma equals 60,899.)
Employed adults with lifetime asthma include persons
diagnosed at ages younger than 18, and persons diagnosed
at ages 18 and above (adult-onset). In Rhode Island, 45%
of adults with lifetime asthma reported adult-onset.5 Therefore, an estimated 27,400 employed Rhode Island adults
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with lifetime asthma experienced the onset of asthma as
adults. (60,900 employed Rhode Island adults with lifetime asthma times 45% of adults with lifetime asthma who
reported adult asthma onset equals 27,411.)
On the basis of previous studies, about 15% of adultonset asthma may be work-related. Therefore, 4,100 adults
employed in Rhode Island may have developed work-related, adult-onset asthma, a portion of which is attributable to SHS (15% of 27,411 employed Rhode Island adults
with adult-onset lifetime asthma).
Current Asthma
Similar logic was used to compute estimates for adults
with current asthma: An estimated 38,880 adults employed
in Rhode Island had current asthma in 2002. Of these
38,880, an estimated 19,440 developed asthma as adults,
and of these 19,440, about 2,916 may have asthma related
to asthma triggers in the workplace, including SHS.

DISCUSSION
Rhode Island’s Smokefree Public Place and Workplace
Law guarantees legal protection from exposure to SHS in
the workplace, thus protecting about 60,900 adult workers with lifetime asthma and 38,880 adult workers with
current asthma.
SHS is one of many factors contributing to work-related asthma.7 Thus, although the new workplace law will
undoubtedly prevent many new cases of work-related adultonset asthma, it will not eliminate all new cases. Nonetheless, every case prevented will preserve quality of life and
lower health care costs, because asthma leads to days missed
from work, ER visits and hospitalizations.9 To illustrate,
consider recent asthma data from Rhode Island’s hospital
discharge data set. In 2002, about $6,420,000 was expended
on adults hospitalized for asthma (642 hospitalizations at an
average cost of $10,000 per hospitalization). With the new
smoke-free workplace law taking effect, this cost, as well as
other costs of asthma morbidity, will probably decline.4
This analysis contains limitations. First, the estimates
are not adjusted for existing workplaces prohibiting smoking; these data are not available. Such corrections would
most likely generate lower estimates than presented here.
Nonetheless, such legislation brings legal protection to an
otherwise voluntary effort. Second, the workforce data contain data on all workforce members regardless of age. Although the preponderance of workers in Rhode Island are
in the 18-64 age group, like the asthma prevalence estimated presented in this analysis. Some are undoubtedly
older and younger. However, the prevalence of asthma is
higher in younger age groups and lower in 65 and older
age groups.
The Public Health & Safety Act of 2004 landmark
legislation legally protects an estimated 60,899 employed
Rhode Island adults with lifetime asthma and an estimated
38,881 employed Rhode Island adults with current asthma
against exposure to workplace SHS.
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A Physician’s Lexicon
The Colorful Words of Medicine, part I
Accurate description, without excessive verbiage, is the hallmark of a
competent physical examination
record. The portrayal of a skin rash, for
example, demands information concerning many of its physical characteristics, including color.
Describing color, to both diagnostician and pathologist, becomes a
meaningful way of conveying a faithful description of the lesion under scrutiny. As with so many aspects of
medical terminology, the two Classical languages - Greek and Latin - each
contribute roots to define the known
colors.
Yellow, for example: The Greek
word for yellow is xanthos, as in xanthine, xanthoma and xanthochromia.
Xanthippe’s name—she was the illtempered wife of Socrates—literally
means the yellow horse. Latin has many
words for yellow, one being galbinus.

This word has evolved into the French
word, jaune, the precursor of the English, jaundice. Flavus is yet another
Latin term for yellow, as in such words
as flavobacteria, riboflavin and flavicid.
And luteus, as in corpus luteus, is a
further Latin word for yellow.
The Greek root for black [melano-]
appears in such terms as melancholy,
melanoma, melena and Melanesia.
The Latin for black, nigrum or niger,
is found in such words as nigritude,
denigrate, substantia nigra and
nigricans. The Latin word, fuscus,
means brownish-black and gives rise
to such English words as obfuscate [to
make dark, to confuse]. It is distantly
related to the English word, furtive,
[concealed, darkened, stealthy.]
The Greek word for white, leukos,
is the etymologic root for leucocyte,
leukemia and leukoderma. And the
Latin words for white [albus and can-

Rhode Island Department of Health
Patricia A. Nolan, MD, MPH, Director of Health

didas ] form the basis for albino, album, albumen, candid, candidate [because Roman candidates for office wore
white togas], candle, incandescent and
Candida. The Latin, pallidus, suggesting paleness more than whiteness, appears in such words as pallor and globus
pallidus. Palliation, to relieve by soothing rather than curing, on the other
hand, is derived from the Latin,
palliatus, meaning to cloak.
The Greek root for grey is polios,
as in poliosis and poliomyelitis. Its
Latin counterpart is griseus, as in
griseofulvin, grizzly and ambergris.
Words derived from the Greek and
Latin terms for yet other colors will be
considered in next month’s column.
– STANLEY M. ARONSON, MD, MPH

Vital Statistics
Edited by Roberta A. Chevoya

Provisional Occurrence Data
from the
Division of Vital Records

Vital Events
Live Births
Deaths
Infant Deaths
Neonatal deaths
Marriages
Divorces
Induced Terminations
Spontaneous Fetal Deaths
Under 20 weeks gestation
20+ weeks gestation

Reporting Period

Underlying
Cause of Death

Rhode Island Monthly
Vital Statistics Report

Diseases of the Heart
Malignant Neoplasms
Cerebrovascular Diseases
Injuries (Accident/Suicide/Homicide)
COPD

Reporting Period
September
2004
Number
993
706
(6)
(2)
1052
257
430
76
(70)
(6)

12 Months Ending with
September 2004
Number
Rates
14,005
13.1*
10,077
9.4*
(77)
5.5#
(61)
4.4#
8,277
7.7*
3,205
3.0*
5,502
392.9#
1,235
88.2#
(1,164)
83.1#
(71)
5.1#

March
2004
Number (a)

Number (a)

Rates (b)

245
222
44
42
58

3,031
2,429
533
476
510

283.3
227.1
49.8
44.5
47.7

12 Months Ending with March 2004
YPLL (c)

4,416.5**
7,406.0 *
850.0**
7,412.0***
412.5**

(a) Cause of death statistics were derived from the
underlying cause of death reported by physicians on
death certificates.
(b) Rates per 100,000 estimated population of
1,069,725
(c) Years of Potential Life Lost (YPLL)

Note: Totals represent vital events which occurred in Rhode Island for the reporting periods listed above. Monthly provisional
totals should be analyzed with caution because the numbers
may be small and subject to seasonal variation.
* Rates per 1,000 estimated population
** Excludes one death of unknown age.

# Rates per 1,000 live births
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NINETY YEARS AGO, MARCH 1915

TWENTY-FIVE YEARS AGO, MARCH 1980

An editorial urged members to contribute “works of fiction which they have read and for which they have no further use” to the newly-established Patients’ Library at Rhode
Island Hospital. “The tedious days of convalescence are a
source of anxiety to the physician, to the nurse and to the
hospital authorities, and anything which will tend to help
pass away the time during the interval of serious illness and
discharge from the hospital will be of decided service.”
A second editorial urged members to obey the Harrison
Law, effective March 1, 1915. The law required physicians
who dispensed their own drugs to use blank forms from
the Commission of the Internal Revenue to order supplies,
to keep a record of all preparations with opium or coca
leaves, and to keep an inventory of those substances in their
possession. “However much we may disagree with its necessity or find fault with the provisions of this law, we must
obey it.”
F.T. Rogers, MD, in “A Study of the Workmen’s Compensation Act as it Affects Rhode Island Physicians,” reported on a survey of 500 practicing RI physicians: 230
responded. Only 92 reported any problem with payment;
104 reported no change in income; 58 reported an increase; 68, a decrease. The author noted, “The testimony
of the profession is almost unanimous that the difficulties
arising from the enforcement of the act are due, not to the
employer, but to the insurance companies, who, in spite of
their great increase in premiums, endeavor to further augment their dividends.”
Roland Hammond, MD, in “The Use of the Autogenous Bone Graft,” reported on two cases. One patient had
had osteomyelitis of the tibia; the second had an “ununited”
fracture of the tibia.

In “Dean’s Message,” Stanley M. Aronson, MD, described “A New Approach to CME.” The medical school
invited practicing physicians to participate, as observer-students, in one of the brief, intensive second-year courses (e.g.,
cardiology, nutrition, nephrology, parasitology).
Guy A. Settipane, MD, in “Aspirin Intolerance Presenting as Chronic Rhinitis,”discussed the case of a 52 yearold woman. The author cautioned that “Aspirin intolerance
should be considered in the diagnosis of unexplained rhinitis, nasal polyps and eosinophilia.”
Siegfried M. Pueschel, MD, Richard E. Frates, MD,
and Don B. Singer, MD, discussed “Small, Post-Dates Infant with Severe Respiratory Distress” in part of a Clinical
Pathological Conference, in the Section of Pathology.
W. Martin DeLuca, PA, Clarence H. Soderberg, Jr, MD,
Raymon S. Riley, MD, Patricia A. O’Shea, MD, and Gayle
S. Griffiths, PA, contributed “Solitary Rhabdomyosarcoma
of the Pericardium: A Case Report and Pathologic Discussion.” A rare tumor was found to be the cause of unexplained
congestive failure.

FIFTY YEARS AGO, MARCH 1955
Alex Burgess, Sr,, MD, Commissioner, Joint Commission on Accreditation of Hospitals, contributed “What
Makes a Good Hospital?” His response: “good people,” not
bricks and mortar.
Bert S. Jeremiah, MD, in “Recent Advances in the
Management of Severe and Extensive Burns,” recommended autoclaved gauze or rayon strips impregnated with
furacin or Vaseline for immediate covering, then for treatment, closed pressure dressings.
Joseph C. O’Connell, MD, in “Extending Voluntary
Medical Care Coverage in Rhode Island,” noted that the
Physicians Sevice Program had enrolled 442,777 Rhode
Islanders after five years of operation. Almost all (871) physicians in the state participated.
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What's in a Name???
GOOD - authentic, honest, just, kind, pleasant, skillful, valid
NEIGHBOR - friend, near
ALLIANCE - affiliation, association, marriage, relationship
CORPORATION - company, business establishment

A Good Partner Makes the Difference
It's Official:
The Rhode Island Medical Society's Insurance Brokerage Corporation
has contracted with
The Good Neighbor Alliance Corporation
to provide their members
Employee Benefits

Specializing in Employee Benefits since 1982
Let the Best in the Business Take Care of Your Employee Benefit Needs.

The Good Neighbor Alliance Corporation
1-800-462-1910 or 401-467-2880
www.goodneighborall.com
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